Publications
Data-sharing publications
Publications
Publications in 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia.
Kothari J, Eyre T, Rismani A, Ediriwickrema K, Edwards D, Galani S, Wilson W, Lawrie A, Clifton-Hadley L, McCarthy H, Collins A, Lewis D, Arulogan S, Auer R, Pratt G, de Tute R, Owen R, D'Sa S.
Br J Haematol. 2024 Aug 19. doi:10.1111/bjh.19706. Epub ahead of print. PMID: 39160671.
19/08/2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E.
J Hematol Oncol. 2024 Aug 6;17(1):61. doi:10.1186/s13045-024-01579-w. PMID: 39107847.
06/08/2024
A randomised phase II trial of Hippocampal Sparing versus Conventional Whole Brain Radiotherapy after surgical resection or radiosurgery in favourable prognosis patients with 1-10 brain metastases
Whitfield GA, Bulbeck H, Clifton-Hadley L, Edwards D, Jefferies S, Jenkinson MD, Griffin M, Handley J, Megias D, Sanghera P, Shaffer R, Short S, Wilson W.

Clinical Oncology, https://doi.org/10.1016/j.clon.2024.07.001
04/07/2024
A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1–10 Brain Metastases
Whitfield GA, Bulbeck H, Clifton-Hadley L, Edwards D, Jefferies S, et al.
Clinical Oncology. https://doi.org/10.1016/j.clon.2024.07.001 Available online 4 July 2024
04/07/2024
A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results
Alexa Childs, Craig Gerrand, Bernadette Brennan, Robin Young, Kenneth S. Rankin, Michael Parry, Jonathan Stevenson, Adrienne M. Flanagan, Rachel M. Taylor, Lorna Fern, Dominique Heymann, Filipa Vance, Jenny Sherriff, Saurabh Singh, Rubina Begum, Sharon L. Forsyth, Krystyna Reczko, Kate Sparksman, William Wilson and Sandra J. Strauss.
Cancers 2024, 16(13), 2351; https://doi.org/10.3390/cancers16132351
27/06/2024
The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma
Beatrice Seddon MD, PhD, Franel Le Grange MD, Rita Simões MSc, Chris Stacey BSc, MSc, Shumona Shelly BSc, MSc, Sharon Forsyth BSc, Laura White BSc, Charles Candish MD, Peter Dickinson MD, Aisha Miah MD, Syed Ali Moinuddin MSc, James Wylie MD, Andre Lopes BSc, MSc.
IntJ Radiat Oncol Biol Phys. ReceivedDec 20, 2023; Accepted for publication May 24, 2024. InPress, Available online 10 June 2024.  
10/06/2024
The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma
Beatrice Seddon, Franel Le Grange, Rita Simões, Chris Stacey, Shumona Shelly, Sharon Forsyth, Laura White, Charles Candish, Peter Dickinson, Aisha Miah, Syed Ali Moinuddin, James Wylie, Andre Lopes.

Int J Radiat Oncol Biol Phys. 2024 Jun10:S0360-3016(24)00687-4. doi: 10.1016/j.ijrobp.2024.05.024. Online ahead ofprint.

https://pubmed.ncbi.nlm.nih.gov/38866214/
10/06/2024
Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia.
Patel B, Kirkwood AA, Rowntree CJ, Alapi KZ, Barretta E, Clifton-Hadley L, Creasey T, Lee S, Marks DI, Moorman AV, Morley N, Patrick P, Rana Z, Rijneveld A, Snowden JA, Fielding AK.

Hemasphere. 2024 Jun 6;8(6):e88. doi: 10.1002/hem3.88. PMID: 38846719; PMCID: PMC11154829.

https://pubmed.ncbi.nlm.nih.gov/38846719/
06/06/2024
Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial.
Maria A. Hawkins et al.
JCO 42, 4006-4006(2024). DOI:10.1200/JCO.2024.42.16_suppl.4006
01/06/2024
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.
Mark David Linch et al.
JCO 42, 5013-5013(2024). DOI:10.1200/JCO.2024.42.16_suppl.5013
01/06/2024
Healthy tissue metabolism assessed by [18F]FDG PET/CT as a marker of prognosis and adverse events in advanced Hodgkin lymphoma patients.
Malaih AA, Kirkwood AA, Johnson P, Radhakrishnan V, Fischer BM, Barrington SF.

https://pubmed.ncbi.nlm.nih.gov/38824206/
01/06/2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas, M., Burridge, S., Kirkwood, A.A. et al.
Blood Cancer J. 14, 66 (2024). 
15/04/2024
Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
Kuhnl A, Roddie C, Kirkwood AA, Chaganti S, Norman J, Lugthart S, et al.
 Br J Haematol. 2024; 00: 1–12. https://doi.org/10.1111/bjh.19453
09/04/2024
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
Bourlon C, Roddie C, Menne T, Norman J, O'Reilly M, Gibb A, Besley C, Chaganti S, Arias CG, Jones C, Dikair A, Allen S, Seymour F, Osborne W, Mathew A, Townsend W, Patten PE, Thoulouli E, Abdulgawad A, Lugthart S, Sanderson R, Kirkwood AA, Kuhnl A.
Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010. Epub ahead of print. PMID: 38572567.
04/04/2024
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia
de Tute R, Counsell N, Clifton-Hadley L, D'Sa S, Pratt G, Campbell G, Campbell L, Sadler R, Townsend W, Popova B, Smith P, Schofield O, Owen R, Auer R.
Leukemia. 2024 Apr;38(4):822-828.
01/04/2024
The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate, and colorectal cancer in the UK.
Lally P, Kennedy F, Smith S, Beeken RJ, Buck C, Thomas C, Counsell N, Wyld L, Martin C, Williams S, Roberts A, Greenfield DM, Gath J, Potts HWW, Latimer N, Smith L, Fisher A.
Cancer Med. 2024 Mar;13(6):e7124.
01/03/2024
The Risk-Screening Converter.
Wald NJ, Duffy SW, Hackshaw A.
J Med Screen. 2023 Mar;30(1):1-2
01/03/2024
Health State Utilities Associated with False-Positive Cancer Screening Results.
Matza LS, Howell TA, Fung ET, Janes SM, Seiden M, Hackshaw A, Nadauld L, Karn H, Chung KC.
Pharmacoecon Open. 2024 Mar;8(2):263-276. doi: 10.1007/s41669-023-00443-w
01/03/2024
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma.
Pan X, AbdulJabbar K, Coelho-Lima J, Grapa AI, Zhang H, Cheung AHK, Baena J, Karasaki T, Wilson CR, Sereno M, Veeriah S, Aitken SJ, Hackshaw A, Nicholson AG, Jamal-Hanjani M; TRACERx Consortium; Swanton C, Yuan Y, Le Quesne J, Moore DA.

Nat Cancer. 2024 Feb;5(2):347-363. doi:10.1038/s43018-023-00694-w. Epub 2024 Jan 10.

https://pubmed.ncbi.nlm.nih.gov/38200244/
01/02/2024
CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, Oporto-Espuelas M, Yeung J, Pinner D, Chu J, Williams L, Ko KY, Walding C, Watts K, Inglott S, Thomas R, Connor C, Adams S, Gravett E, Gilmour K, Lal A, Kunaseelan S, Popova B, Lopes A, Ngai Y, Hackshaw A, Kokalaki E, Carulla MB, Mullanfiroze K, Lazareva A, Pavasovic V, Rao A, Bartram J, Vora A, Chiesa R, Silva J, Rao K, Bonney D, Wynn R, Pule M, Hough R, Amrolia PJ.
Blood. 2024 Jan 11;143(2):118-123
11/01/2024
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, Venneri L, Fontana M, Hawkins PN, Gillmore J, Lachmann HJ, Mahmood S, Whelan C, Kirkwood AA, Wechalekar A.
Haematologica. 2024 Jan 11. doi: 10.3324/haematol.2023.284348. Epub ahead of print. PMID: 38205538.
11/01/2024
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting.
Hackshaw A, Fajardo O, Dafni U, Gelderblom H, Garrido P, Siena S, Taylor MH, Bordogna W, Nikolaidis C.
JCO Precis Oncol. 2024 Jan;8(1):e2300334
01/01/2024
Publications in 2023
A robust and validated integrated prognostic index for defining risk groups in adult ALL: A EWALL collaborative study.
Enshaei A, Joy M, Butler ER, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, Moorman AV.
Blood Adv. 2023 Dec 19:bloodadvances.2023011661. doi: 10.1182/bloodadvances.2023011661. Epub ahead of print. PMID: 38113467.
19/12/2023
Impact of MYC and BCL2 double expression on outcomes in Primary CNS Lymphoma: a UK multicenter analysis.
Poynton E, Chernucha E, Day JW, Prodger C Dr, Hopkins D, Rakesh P, O'Neill T, Thakrar N, Akarca A, Jamal E, Ali AS, Kirkwood AA, Pomplun S, Marafioti T, Calaminici M, Greaves P, Chaganti S, McKay P, Smith J, Eyre TA, Martinez-Calle N, Cwynarski K, Fox CP, Okosun J.

Blood Adv. 2023 Dec 1:bloodadvances.2023011426. doi: 10.1182/bloodadvances.2023011426. Epub ahead of print

https://pubmed.ncbi.nlm.nih.gov/38039509/
01/12/2023
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
Wilson, M.R., Kirkwood, A.A., Wong Doo, N., Soussain, C., Choquet, S., Lees, C., Fox, C., Preston, G., Ahearne, M., Strüßmann, T., Clavert, A., Rusconi, C., Ku, M., Khwaja, J., Narkhede, M., Lewis, K., Durot, E., Smith, J., Renaud, L., Ferreri, A.J.M., el-Galaly, T., Cwynarski, K., McKay, P. and Eyre, T.A.
AmJ Hematol. 2023 Nov 30https://doi.org/10.1002/ajh.27167
30/11/2023
Stage at Diagnosis Following Delay to Interval Scans for Indeterminate Nodules in Lung Cancer Screening: An Observational Study Examining the Outcomes of CHEST Expert Panel Recommendations
Creamer AW, Horst C, Dickson JL, Tisi S, Hall H, Verghese P, Prendecki R, Bhamani A, Khaw CR, McCabe J, Limani T, Gyertson K, Hacker AM, Teague J, Farrelly L, Dawadi S, Hackshaw A, Devaraj A, Nair A, Janes SM; SUMMIT Consortium.
Chest. 2023 Oct 31:S0012-3692(23)05678-7. doi: 10.1016/j.chest.2023.10.033
31/10/2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, Berkahn L, Barrington SF, Radford J, Federico M, Kirkwood AA, Johnson PWM.
J Clin Oncol. 2023 Oct 26:JCO2301177. doi: 10.1200/JCO.23.01177. Epub ahead of print. PMID: 37883739.
26/10/2023
Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL.
O'Connor D, Joy M, Enshaei A, Kirkwood AA, Kearns PR, Samarasinghe S, Moppett JP, Moorman AV, Vora A.
Blood Adv. 2023 Oct 12:bloodadvances.2023011267. doi: 10.1182/bloodadvances.2023011267. Epub ahead of print. PMID: 37824845.
12/10/2023
CD19/CD22 targeting with co-transduced CAR T-cells to prevent antigen negative relapse after CAR T-cell therapy of B-ALL.
Sara Ghorashian, Giovanna Lucchini, Rachel Richardson, Kyvi Nguyen, Craig Terris, Aleks Guvenel, Macarena Oporto Espuelas, Jenny Yeung, Danielle Pinner, Jan Chu, Lindsy Williams, Ka-Yuk Ko, Chloe Walding, Kelly Watts, Sarah Inglott, Rebecca Thomas, Christopher Connor, Stuart Paul Adams, Emma Gravett, Kimberley C Gilmour, Alka Lal, Bilyana Popova, Sangeetha Kunaseelan, Andre Lopes, Mr, Yenting Ngai, Allan Hackshaw, Evangelia K Kokalaki, Milena Balasch-Carulla, Khushnuma Mullanfiroze, Arina Lazareva, Vesna Pavasovic, Anupama Rao, Jack Bartram, Ajay Vora, Robert Chiesa, Juliana M Furtado Silva, Kanchan Rao, Denise Kathleen Bonney, Robert Wynn, Martin Pule, Rachael E Hough, Professor, Persis J. Amrolia.
2023 Aug 30;blood.2023020621. doi: 10.1182/blood.2023020621. Online ahead of print.
30/08/2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM, Cremaschi P, Wetterskog D, Jayaram A, Wong SQ, Williams S, Pasam A, Trigos A, Trujillo B, Grist E, Friedrich S, Vainauskas O, Parry M, Ismail M, Devlies W, Wingate A, Linch M, Naceur-Lombardelli C; PEACE consortium; Swanton C, Jamal-Hanjani M, Lise S, Sandhu S, Attard G.
Nat Commun. 2023 Aug 10;14(1):4823.
10/08/2023
Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era.
Klein EA, Madhavan S, Beer TM, Bettegowda C, Liu MC, Hartman AR, Hackshaw A.
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1;32(8):1003-1010
01/08/2023
Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease.
Meyer, Tim, Sevasti Galani, Andre Lopes, and Arndt Vogel.
J Hepatol. 2023 Aug;79(2):e73-e76. doi: 10.1016/j.jhep.2023.04.012. Epub 2023 Apr 21.
01/08/2023
Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.
Cheok KPL, Kirkwood AA, Creasey T, Tholouli E, Chaganti S, Mathew A, Dulobdas V, Irvine D, Besley C, Neil L, Lown R, Menne T, Townsend W, Kuhnl A, O'Reilly M, Sanderson R, Sanchez E, Roddie C.
Leuk Lymphoma. 2023 Aug 21:1-5. doi: 10.1080/10428194.2023.2248329. Epub ahead of print. PMID: 37602678.
01/08/2023
Transcriptional signatures associated with persisting CD19 CAR T-cells in children with leukaemia.
Nathaniel D. Anderson, Jack Birch, Theo Accogli, Ignacio Criado, Eleonora Khabirova, Conor Parks, Yvette Wood, Matthew D. Young, Tarryn Porter, Rachel Richardson, Sarah J. Albon, Bilyana Popova, Andre Lopes, Robert Wynn, Rachael Hough, Satyen H. Gohil, Martin Pule, Persis J. Amrolia, Sam Behjati & Sara Ghorashian
Nat Med 29, 1700–1709 (2023). https://doi.org/10.1038/s41591-023-02415-3
06/07/2023
Prevalence and clinical characteristics of non-malignant CT detected incidental findings in the SUMMIT lung cancer screening cohort.
Tisi S, Creamer AW, Dickson J, Horst C, Quaife S, Hall H, Verghese P, Gyertson K, Bowyer V, Levermore C, Hacker AM, Teague J, Farrelly L, Nair A, Devaraj A, Hackshaw A, Hurst JR; SUMMIT Consortium; Janes
BMJ Open Respir Res. 2023 Jun;10(1):e001664
01/06/2023
Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia.
Leongamornlert D, Gutiérrez-Abril J, Lee SW, Barretta E, Creasey T, Gundem G, Levine MF, Arango Ossa JE, Liosis K, Medina-Martinez JS, Zuborne Alapi K, Kirkwood AA, Clifton-Hadley L, Patrick P, Jones D, O'Neill LJ, Butler AP, Harrison CJ, Campbell PJ, Patel B, Moorman AV, Fielding AK, Papaemmanuil E.

Blood Adv. 2023 Mar 3:bloodadvances.2022008992. doi: 10.1182/bloodadvances.2022008992. Epub ahead of print. PMID: 36867579.

https://pubmed.ncbi.nlm.nih.gov/36867579/
03/05/2023
Body composition and lung cancer-associated cachexia in TRACERx.
Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, Kidd AC, Frankell AM, Watkins TBK, Martínez-Ruiz C, Puttick C, Black JRM, Huebner A, Bakir MA, Sokač M, Collins S, Veeriah S, Magno N, Naceur-Lombardelli C, Prymas P, Toncheva A, Ward S, Jayanth N, Salgado R, Bridge CP, Christiani DC, Mak RH, Bay C, Rosenthal M, Sattar N, Welsh P, Liu Y, Perrimon N, Popuri K, Beg MF, McGranahan N, Hackshaw A, Breen DM, O'Rahilly S, Birkbak NJ, Aerts HJWL; TRACERx Consortium; Jamal-Hanjani M, Swanton C.

Nat Med. 2023 Apr;29(4):846-858. doi: 10.1038/s41591-023-02232-8. Epub 2023 Apr 12.
29/04/2023
The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
O'Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, Bloye G, Farah N, Rahman S, Hancock J, Bateman C, Inglott S, Mee J, Herrero J, Van Loo P, Moorman AV, Vora A, Mansour MR.
J Clin Oncol. 2023 Apr 25:JCO2202734. doi: 10.1200/JCO.22.02734. Epub ahead of print. PMID: 37098241.
25/04/2023
CAR T in patients with large B-cell lymphoma not fit for autologous transplant.
Kuhnl A, Kirkwood AA, Roddie C, Menne T, Tholouli E, Bloor A, Besley C, Chaganti S, Osborne W, Norman J, Gibb A, Sharplin K, Cuadrado M, Correia de Farias M, Cheok K, Neill L, Latif AL, González Arias C, Uttenthal B, Jones C, Johnson R, McMillan A, Sanderson R, Townsend W.

Br J Haematol. 2023 Apr 20. doi: 10.1111/bjh.18810. Epub ahead of print. PMID: 37082780.

https://pubmed.ncbi.nlm.nih.gov/37082780/ 
20/04/2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L'Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium; Birkbak NJ, McGranahan N, Swanton C.

Nature. 2023 Apr;616(7957):553-562doi: 10.1038/s41586-023-05776-4.

https://pubmed.ncbi.nlm.nih.gov/37055640/
13/04/2023
The evolution of lung cancer and impact of subclonal selection in TRACERx.
Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A, Hill MS, Grigoriadis K, Moore DA, Black JRM, Liu WK, Thol K, Pich O, Watkins TBK, Naceur-Lombardelli C, Cook DE, Salgado R, Wilson GA, Bailey C, Angelova M, Bentham R, Martínez-Ruiz C, Abbosh C, Nicholson AG, Le Quesne J, Biswas D, Rosenthal R, Puttick C, Hessey S, Lee C, Prymas P, Toncheva A, Smith J, Xing W, Nicod J, Price G, Kerr KM, Naidu B, Middleton G, Blyth KG, Fennell DA, Forster MD, Lee SM, Falzon M, Hewish M, Shackcloth MJ, Lim E, Benafif S, Russell P, Boleti E, Krebs MG, Lester JF, Papadatos-Pastos D, Ahmad T, Thakrar RM, Lawrence D, Navani N, Janes SM, Dive C, Blackhall FH, Summers Y, Cave J, Marafioti T, Herrero J, Quezada SA, Peggs KS, Schwarz RF, Van Loo P, Miedema DM, Birkbak NJ, Hiley CT, Hackshaw A, Zaccaria S; TRACERx Consortium; Jamal-Hanjani M, McGranahan N, Swanton C.

Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 12.

https://pubmed.ncbi.nlm.nih.gov/37046096/
12/04/2023
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M, Young G, Molina-Arcas M, de Carné Trécesson S, Anastasiou P, Fendler A, Au L, Shepherd STC, Martínez-Ruiz C, Puttick C, Black JRM, Watkins TBK, Kim H, Shim S, Faulkner N, Attig J, Veeriah S, Magno N, Ward S, Frankell AM, Al Bakir M, Lim EL, Hill MS, Wilson GA, Cook DE, Birkbak NJ, Behrens A, Yousaf N, Popat S, Hackshaw A; TRACERx Consortium; CAPTURE Consortium; Hiley CT, Litchfield K, McGranahan N, Jamal-Hanjani M, Larkin J, Lee SH, Turajlic S, Swanton C, Downward J, Kassiotis G.
Nature. 2023 Apr;616(7957):563-573. doi: 10.1038/s41586-023-05771-9. Epub 2023 Apr 12.
12/04/2023
Genomic-transcriptomic evolution in lung cancer and metastasis.
Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C, Toncheva A, Prymas P, Rowan A, Ward S, Cubitt L, Athanasopoulou F, Pich O, Karasaki T, Moore DA, Salgado R, Colliver E, Castignani C, Dietzen M, Huebner A, Al Bakir M, Tanić M, Watkins TBK, Lim EL, Al-Rashed AM, Lang D, Clements J, Cook DE, Rosenthal R, Wilson GA, Frankell AM, de Carné Trécesson S, East P, Kanu N, Litchfield K, Birkbak NJ, Hackshaw A, Beck S, Van Loo P, Jamal-Hanjani M; TRACERx Consortium; Swanton C, McGranahan N.

Nature. 2023 Apr;616(7957):543-552. doi: 10.1038/s41586-023-05706-4. Epub 2023 Apr 12.
12/04/2023
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.
Karasaki T, Moore DA, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA, Watkins TBK, Grigoriadis K, Huebner A, Hill MS, Frankell AM, Abbosh C, Puttick C, Zhai H, Gimeno-Valiente F, Saghafinia S, Kanu N, Dietzen M, Pich O, Lim EL, Martínez-Ruiz C, Black JRM, Biswas D, Campbell BB, Lee C, Colliver E, Enfield KSS, Hessey S, Hiley CT, Zaccaria S, Litchfield K, Birkbak NJ, Cadieux EL, Demeulemeester J, Van Loo P, Adusumilli PS, Tan KS, Cheema W, Sanchez-Vega F, Jones DR, Rekhtman N, Travis WD, Hackshaw A, Marafioti T, Salgado R, Le Quesne J, Nicholson AG; TRACERx Consortium; McGranahan N, Swanton C, Jamal-Hanjani M.
Nat Med. 2023 Apr;29(4):833-845. doi: 10.1038/s41591-023-02230-w. Epub 2023 Apr12.
12/04/2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicine.
Horgan D, Capoluongo E, Dube F, Trapani D, Malapelle U, Rovite V, Omar MI, Alix-Panabières C, Rutkowski P, Bayle A, Hackshaw A, Hofman P, Subbiah V.
Diagnosis (Berl). 2023 Apr 10;10(4):356-362
10/04/2023
Lung adenocarcinoma promotion by air pollutants.
Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, Kuan FC, Marongiu F, Evans EJ Jr, Moore DA, Rodrigues FS, Pich O, Bakker B, Cha H, Myers R, van Maldegem F, Boumelha J, Veeriah S, Rowan A, Naceur-Lombardelli C, Karasaki T, Sivakumar M, De S, Caswell DR, Nagano A, Black JRM, Martínez-Ruiz C, Ryu MH, Huff RD, Li S, Favé MJ, Magness A, Suárez-Bonnet A, Priestnall SL, Lüchtenborg M, Lavelle K, Pethick J, Hardy S, McRonald FE, Lin MH, Troccoli CI, Ghosh M, Miller YE, Merrick DT, Keith RL, Al Bakir M, Bailey C, Hill MS, Saal LH, Chen Y, George AM, Abbosh C, Kanu N, Lee SH, McGranahan N, Berg CD, Sasieni P, Houlston R, Turnbull C, Lam S, Awadalla P, Grönroos E, Downward J, Jacks T, Carlsten C, Malanchi I, Hackshaw A, Litchfield K; TRACERx Consortium; DeGregori J, Jamal-Hanjani M, Swanton C.
Nature. 2023 Apr;616(7955):159-167. doi: 10.1038/s41586-023-05874-3. Epub 2023 Apr 5.
05/04/2023
The evolution of non-small cell lung cancer metastases in TRACERx
Al Bakir M, Huebner A, Martínez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S, Laycock J, Johnson D, Rowan A, Razaq M, Akther M, Naceur-Lombardelli C, Prymas P, Toncheva A, Hessey S, Dietzen M, Colliver E, Frankell AM, Bunkum A, Lim EL, Karasaki T, Abbosh C, Hiley CT, Hill MS, Cook DE, Wilson GA, Salgado R, Nye E, Stone RK, Fennell DA, Price G, Kerr KM, Naidu B, Middleton G, Summers Y, Lindsay CR, Blackhall FH, Cave J, Blyth KG, Nair A, Ahmed A, Taylor MN, Procter AJ, Falzon M, Lawrence D, Navani N, Thakrar RM, Janes SM, Papadatos-Pastos D, Forster MD, Lee SM, Ahmad T, Quezada SA, Peggs KS, Van Loo P, Dive C, Hackshaw A, Birkbak NJ, Zaccaria S; TRACERx Consortium; Jamal-Hanjani M, McGranahan N, Swanton C.
Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 1.
01/04/2023
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L'Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium; Birkbak NJ, McGranahan N, Swanton C.
Nature. 2023 Apr;616(7957):525-533
01/04/2023
Faecal immunochemical testing for haemoglobin in detecting bowel polyps in symptomatic patients: multicentre prospective cohort study.
Bath MF, Malhi A, Ayling RM, Seward E, Pritchard-Jones K, Laszlo HE, Hackshaw A, Machesney MR.
BJS Open. 2023 Mar 7;7(2):zrac161
07/03/2023
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, Fail T, Nicholson E, Fletcher K, Linton KM, Parsons KE, Elmusharaf N, Eccersley L, Eyre TA, Chaganti S, Smith J, Thakrar N, Kutilina A, Calimeri T, Martinez-Calle N, El-Sharkawi D, Osborne W, Illerhaus G, Fox CP, Ferreri AJM, Schorb E, Cwynarski K.

Haematologica. 2023 Mar 1;108(3):882-888. doi: 10.3324/haematol.2022.281640. PMID: 36300776; PMCID: PMC9973475.

https://pubmed.ncbi.nlm.nih.gov/36300776/
01/03/2023
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
Fiaccadori V, Neven A, Fortpied C, Aurer I, Andre M, Federico M, Counsell N, Phillips EH, Clifton-Hadley L, Barrington SF, Illidge T, Radford J, Raemaekers JMM.
Br J Haematol. 2023 Mar;200(6):731-739.
https://pubmed.ncbi.nlm.nih.gov/36541117/
01/03/2023
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor AJ, Jones CH, Uttenthal BJ, Johnson RJ, Sanderson R, Cheok KP, Marzolini MAV, Townsend WM, O'Reilly M, Kirkwood AA, Kuhnl A.

Blood Adv. 2023 Feb 1:bloodadvances.2022009019. doi: 10.1182/bloodadvances.2022009019. Epub ahead of print. PMID: 36724512.

https://pubmed.ncbi.nlm.nih.gov/36724512/
01/02/2023
Uptake of invitations to a lung health check offering low-dose CT lung cancer screening among an ethnically and socioeconomically diverse population at risk of lung cancer in the UK (SUMMIT): a prospective, longitudinal cohort study.
Dickson JL, Hall H, Horst C, Tisi S, Verghese P, Mullin AM, Teague J, Farrelly L, Bowyer V, Gyertson K, Bojang F, Levermore C, Anastasiadis T, McCabe J, Navani N, Nair A, Devaraj A, Hackshaw A, Quaife SL, Janes SM; SUMMIT consortium.
Lancet Public Health. 2023 Feb;8(2):e130-e140
01/02/2023
The SUMMIT Study: Utilising a written 'Next Steps' information booklet to prepare participants for potential lung cancer screening results and follow-up.
Bhamani A, Horst C, Bojang F, Quaife SL, Dickson JL, Tisi S, Hall H, Verghese P, Creamer A, Prendecki R, McCabe J, Gyertson K, Bowyer V, El-Emir E, Cotton A, Mehta S, Levermore C, Mullin AM, Teague J, Farrelly L, Nair A, Devaraj A, Hackshaw A; SUMMIT consortium; Janes SM.
Lung Cancer. 2023 Feb;176:75-81
01/02/2023
T-replete cord transplants give superior outcomes in high risk and relapsed/refractory paediatric myeloid malignancy.
Horgan C, Mullanfiroze K, Rauthan A, Patrick K, Butt NA, Mirci-Danicar O, O'Connor O, Furness CL, Deshpande A, Lawson S, Broderick V, Evans P, Gibson BE, Roberts W, Ali S, Galani S, Kirkwood AA, Jovanovic J, Dillon RJ, Virgo P, James B, Rao K, Amrolia PJ, Wynn R.

Blood Adv. 2023 Jan 17:bloodadvances.2022009253. doi:10.1182/bloodadvances.2022009253. Epub ahead of print. PMID: 36649566.

https://pubmed.ncbi.nlm.nih.gov/36649566/

17/01/2023
Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial.
Peggs, Karl S., Sarah J. Albon, Macarena Oporto Espuelas, Catherine Irving, Rachel Richardson, Joan Casanovas-Company, Rebecca Wallace et al.
Cytotherapy 25, no. 1 (2023): 82-93.
01/01/2023
Publications in 2022
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
RAINBO Research Consortium.

Int J Gynecol Cancer. 2023;33:109-117. 

https://ijgc.bmj.com/content/early/2022/12/20/ijgc-2022-004039
20/12/2022
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Yong K, Wilson W, de Tute R, Camilleri M, Ramasamy K, Streetly M, et al.

Lancet Haematol. 2022; in press.

https://pubmed.ncbi.nlm.nih.gov/36529145/
15/12/2022
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, Gross S, Melton C, Fields AP, Liu Q, Zhang N, Fung ET, Kurtzman KN, Amini H, Betts C, Civello D, Freese P, Calef R, Davydov K, Fayzullina S, Hou C, Jiang R, Jung B, Tang S, Demas V, Newman J, Sakarya O, Scott E, Shenoy A, Shojaee S, Steffen KK, Nicula V, Chien TC, Bagaria S, Hunkapiller N, Desai M, Dong Z, Richards DA, Yeatman TJ, Cohn AL, Thiel DD, Berry DA, Tummala MK, McIntyre K, Sekeres MA, Bryce A, Aravanis AM, Seiden MV, Swanton C.
Cancer Cell. 2022 Dec 12;40(12):1537-1549.e12. doi: 10.1016/j.ccell.2022.10.022. Epub 2022 Nov 17.
12/12/2022
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
David J Propper, Fangfei Gao, Mark P Saunders, Debashis Sarker, John A Hartley, Victoria J Spanswick, Helen L Lowe, Louise D Hackett, Tony T Ng, Paul R Barber, Gregory E Weitsman, Sarah Pearce, Laura White, Andre Lopes, Sharon Forsyth, Daniel Hochhauser.
British Journal of Cancer. 2022 Nov 9. doi: 10.1038/s41416-022-02015-x. Online ahead of print.
09/11/2022
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P, Kelly GP, Biswas D, Marani M, Hancock DC, Creasy T, Sachsenmeier K, Swanton C; TRACERx consortium, Downward J, de Carné Trécesson S.
Nat Commun. 2022 Sep 26;13(1):5632. doi: 10.1038/s41467-022-33290-0.
26/09/2022
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Bahl A, Wilson W, Ball J, Renninson E, Dubey S, Bravo A, et al.

Breast. 2022 Sep 24;66:69-76

https://pubmed.ncbi.nlm.nih.gov/36194950/
24/09/2022
Immunotherapy with CD25/71 allodepleted T-cells to improve T-cell reconstitution after MUD HSCT - a randomised trial.
Peggs KSea.
Cytotherapy(in press). 2022.
20/09/2022
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
Beaton L, Tregidgo HFJ, Znati SA, Forsyth S, Counsell N, Clarkson MJ, et al.
J Vasc Interv Radiol. 2022;33(9):1034-44.e29.
01/09/2022
Peripartum outcomes after combined myo-inositol, probiotics, and micronutrient supplementation from preconception: the NiPPeR randomized controlled trial.
Chan SY, Yong HEJ, Chang HF, Barton SJ, Galani S, Zhang H, et al.
AmJ Obstet Gynecol MFM. 2022;4(6):100714. Online ahead of print.
13/08/2022
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.
Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, McKinna F, et al.
Radiother Oncol. 2022;173:77-83.
01/08/2022
. Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL, Kirkwood AA, Menne T, Tholouli E, Chaganti S, Mathew A, et al.
Leuk Lymphoma. 2022:1-5.
01/08/2022
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al.

Br J Haematol. 2022;198(3):492-502.

https://pubmed.ncbi.nlm.nih.gov/35485402/
01/08/2022
The COVANOS trial - insight into post-COVID olfactory dysfunction and the role of smell training.
Lechner M, Liu J, Counsell N, Gillespie D, Chandrasekharan D, Ta NH, et al.
Rhinology.2022.
28/07/2022
Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (Br. J. Haematol. 2018; 182: 46-62): Risk assessment of potential CAR T candidates receiving a covalent Bruton tyrosine kinase inhibitor for relapsed/refractory disease.
O'Reilly MA, Sanderson R, Wilson W, Iyengar S, Lambert J, McCulloch R, et al.
BrJ Haematol. 2022.
27/07/2022
Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry.
Tisi S, Dickson JL, Horst C, Quaife SL, Hall H, Verghese P, et al.
EurRespir J. 2022. Online ahead of print.
26/07/2022
Telephone risk-based eligibility assessment for low-dose CT lung cancer screening.
Dickson JL, Hall H, Horst C, Tisi S, Verghese P, Mullin AM, et al.
Thorax.2022.
21/07/2022
Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
Sidhu J, Masurekar AN, Gogoi MP, Fong C, Ioannou T, Lodhi T, et al.
Br J Haematol. 2022;198(1):142-50.
01/07/2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, et al
IntJ Gynecol Cancer. 2022;32(6):761-8.
06/06/2022
A local human Vdelta1 T cell population is associated with survival in nonsmall-cell lung cancer.
Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, et al.
NatCancer. 2022;3(6):696-709.
03/06/2022
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.
Yin Wu, Dhruva Biswas, Ieva Usaite , Mihaela Angelova, Stefan Boeing, Takahiro Karasaki , Selvaraju Veeriah, Justyna Czyzewska-Khan, Cienne Morton, Magdalene Joseph, Sonya Hessey, James Reading, Andrew Georgiou, Maise Al-Bakir, TRACERx Consortium; Nicholas McGranahan, Mariam Jamal-Hanjani, Allan Hackshaw, Sergio A Quezada, Adrian C Hayday , Charles Swanton.
Nat Cancer. 2022 Jun;3(6):696-709. doi: 10.1038/s43018-022-00376-z. Epub 2022 May 30.
03/06/2022
The reporting of pulmonary nodule results by letter in a lung cancer screening setting.
Dickson JL, Bhamani A, Quaife SL, Horst C, Tisi S, Hall H, et al.
Lung Cancer. 2022;168:46-9.
01/06/2022
Visualising harms in publications of randomised controlled trials: consensus and recommendations.
Phillips R, Cro S, Wheeler G, Bond S, Morris TP, Creanor S, et al.

BMJ. 2022;377:e068983.

https://www.bmj.com/content/377/bmj-2021-068983
16/05/2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, et al.
Blood Adv. 2022;6(9):2920-6.
10/05/2022
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter >/= 7 cm) non-small cell lung cancers.
Zhang JT, Dong S, Ji LY, Zhou JY, Chen ZH, Su J, et al.
ThoracCancer. 2022;13(9):1333-41.
01/05/2022
Intermittent PI3Kdelta inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S, Ramirez-Suastegui C, Li Y, King E, Chudley L, Thomas J, et al.
Nature.2022;605(7911):741-6.
01/05/2022
Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non-small cell lung cancers.
Zhang JT, Dong S, Ji LY, Zhou JY, Chen ZH, Su J, Zhu QG, Wang MM, Ke EE, Sun H, Li XT, Yang JJ, Zhou Q, Zhang XC, Gao X, Yang XN, Xia X, Yi X, Zhong WZ, Wu YL
Thorac Cancer. 2022 May;13(9):1333-1341. doi: 10.1111/1759-7714.14393. Epub 2022 Apr 8.
01/05/2022
Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation.
Hough R, Lopes A, Patrick P, Russell N, Raj K, Tholouli E, et al.
Blood Adv. 2022;6(7):2414-26.

https://www.ncbi.nlm.nih.gov/pubmed/34700343
12/04/2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
David I Marks, Amy A Kirkwood, Clare J Rowntree, Melanie Aguiar, Katharine E Bailey, Brendan Beaton, Paul Cahalin, Anna Z Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H Goldstone, Richard Kelly, Emma Lawrie, SooWah Lee, Andrew K McMillan, Mary Frances McMullin, Tobias F Menne, Rachel J Mitchell, Anthony V Moorman, Bela Patel, Pip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K Fielding.

https://www.sciencedirect.com/science/article/pii/S2352302622000382
01/04/2022
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
David I Marks, Laura Clifton-Hadley, Mhairi Copland, Jiaull Hussain, Tobias F Menne, Andrew McMillan, Anthony V Moorman, Nicholas Morley, Dina Okasha, Bela Patel, Pip Patrick, Michael N Potter, Clare J Rowntree, Amy A Kirkwood, Adele K Fielding.

https://www.sciencedirect.com/science/article/pii/S2352302622000369
01/04/2022
An app with brief behavioural support to promote physical activity after a cancer diagnosis (APPROACH): study protocol for a pilot randomised controlled trial.
Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, et al.
PilotFeasibility Stud. 2022;8(1):74.
29/03/2022
Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials
Sidhu, J, Masurekar, AN, Gogoi, MP, Fong, C, Ioannou, T, Lodhi, T, Parker C, Liu J, Kirkwood AA, Moorman AV, Das K, Goulden NJ, Vora A, Saha V, Krishnan S.
Br J Haematol. 2022 March 29
29/03/2022
Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial.
Khaw, P., Do, V., Lim, K., Cunninghame, J., Dixon, J., Vassie, J., Bailey, M., Johnson, C., Kahl, K., Gordon, C., Cook, O., Foo, K., Fyles, A., Powell, M., Haie-Meder, C., D'Amico, R., Bessette, P., Mileshkin, L., Creutzberg, C. L. and Moore, A.
Clin Oncol (R Coll Radiol). 2022Mar;34(3):198-204.
https://www.ncbi.nlm.nih.gov/pubmed/34903431
01/03/2022
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study
Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, et al.
Leukemia. 2022;36(3):625-36.

https://www.ncbi.nlm.nih.gov/pubmed/34657128
01/02/2022
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Chan, W. Y. Counsell, N. de Tute, R. De-Silva, D. Phillips, E. H. Cavenagh, J. Adedayo, T. Braganca, N. Roddie, C. Streetly, M. Schey, S. Koh, M. B. C. Crowe, J. Morris, T. C. Cook, G. Clifton-Hadley, L. Rabin, N. Owen, R. G. Popat, R. Yong, K. L. Padimac investigators
https://www.ncbi.nlm.nih.gov/pubmed/34636043
01/02/2022
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth, C., Tarnawski, R., Tyulyandina, A., Pignata, S., Gilbert, L., Kaen, D., Rubio, M. J., Frentzas, S., Beiner, M., Magallanes-Maciel, M., Farrelly, L., Choi, C. H., Berger, R., Lee, C., Vulsteke, C., Hasegawa, K., Braicu, E. I., Wu, X., McKenzie, J., Lee, J. J. and Makker, V.
Int J Gynecol Cancer. 2022 Jan;32(1):93-100. 
https://www.ncbi.nlm.nih.gov/pubmed/34799418
01/01/2022
International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System.
Lechner M, Takahashi Y, Turri-Zanoni M, Ferrari M, Liu J, Counsell N, et al
JNeurol Surg Part B. 2022.
01/01/2022
Publications in 2021
Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset.
Vivekanandan S, Fenwick JD, Counsell N, Panakis N, Stuart R, Higgins GS, Hawkins MA.

Radiother Oncol. 2021 Dec;165:119-125.

https://www.ncbi.nlm.nih.gov/pubmed/34718053

01/12/2021
Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.
Creasey, T. Barretta, E. Ryan, S. L. Butler, E. Kirkwood, A. A. Leongamornlert, D. Papaemmanuil, E. Patrick, P. Clifton-Hadley, L. Patel, B. Menne, T. McMillan, A. K. Harrison, C. J. Rowntree, C. J. Morley, N. Marks, D. I. Fielding, A. K. Moorman, A. V.
https://www.ncbi.nlm.nih.gov/pubmed/34788984
18/11/2021
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma
Cutter, D. J. Ramroth, J. Diez, P. Buckle, A. Ntentas, G. Popova, B. Clifton-Hadley, L. Hoskin, P. J. Darby, S. C. Radford, J. Illidge, T.
https://www.ncbi.nlm.nih.gov/pubmed/34388007
10/11/2021
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R., Byrne, F., Horswell, S., Fotiadis, N., Hazell, S., Nicol, D., Shepherd, S. T. C., Fendler, A., Mason, R., Del Rosario, L., Edmonds, K., Lingard, K., Sarker, S., Mangwende, M., Carlyle, E., Attig, J., Joshi, K., Uddin, I., Becker, P. D., Sunderland, M. W., Akarca, A., Puccio, I., Yang, W. W., Lund, T., Dhillon, K., Vasquez, M. D., Ghorani, E., Xu, H., Spencer, C., Lopez, J. I., Green, A., Mahadeva, U., Borg, E., Mitchison, M., Moore, D. A., Proctor, I., Falzon, M., Pickering, L., Furness, A. J. S., Reading, J. L., Salgado, R., Marafioti, T., Jamal-Hanjani, M., Consortium, Peace, Kassiotis, G., Chain, B., Larkin, J., Swanton, C., Quezada, S. A., Turajlic, S. and Consortium, T. RACERx Renal
Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. 
https://www.ncbi.nlm.nih.gov/pubmed/34715028
08/11/2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Roddie, C. Dias, J. O'Reilly, M. A. Abbasian, M. Cadinanos-Garai, A. Vispute, K. Bosshard-Carter, L. Mitsikakou, M. Mehra, V. Roddy, H. Hartley, J. A. Spanswick, V. Lowe, H. Popova, B. Clifton-Hadley, L. Wheeler, G. Olejnik, J. Bloor, A. Irvine, D. Wood, L. Marzolini, M. A. V. Domning, S. Farzaneh, F. Lowdell, M. W. Linch, D. C. Pule, M. A. Peggs, K. S.
https://www.ncbi.nlm.nih.gov/pubmed/34464155
20/10/2021
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution
Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell DR, Lu WT, Dietzen M, Galanos P, Evangelou K, Bellelli R, Lim EL, Watkins TBK, Rowan A, Teixeira VH, Zhao Y, Chen H, Ngo B, Zalmas LP, Al Bakir M, Hobor S, Grönroos E, Pennycuick A, Nigro E, Campbell BB, Brown WL, Akarca AU, Marafioti T, Wu MY, Howell M, Boulton SJ, Bertoli C, Fenton TR, de Bruin RAM, Maya-Mendoza A, Santoni-Rugiu E, Hynds RE, Gorgoulis VG, Jamal-Hanjani M, McGranahan N, Harris RS, Janes SM, Bartkova J, Bakhoum SF, Bartek J, Kanu N, Swanton C; TRACERx Consortium
Cancer Discov. 2021 Oct;11(10):2456-2473. 
https://pubmed.ncbi.nlm.nih.gov/33947663/ 
01/10/2021
IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial
Mitchell, R. J. Kirkwood, A. A. Barretta, E. Clifton-Hadley, L. Lawrie, E. Lee, S. Leongamornlert, D. Marks, D. I. McMillan, A. K. Menne, T. F. Papaemmanuil, E. Patel, B. Patrick, P. Rowntree, C. J. Zareian, N. Alapi, K. Z. Moorman, A. V. Fielding, A. K.
https://www.ncbi.nlm.nih.gov/pubmed/34477813
14/09/2021
Using DNA sequencing data to quantify T cell fraction and therapy response
Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA, Jamal-Hanjani M; TRACERx Consortium, Swanton C, McGranahan N
Nature. 2021 Sep;597(7877):555-560.
https://pubmed.ncbi.nlm.nih.gov/34497419/ 
01/09/2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Fabio Conforti , Laura Pala, Eleonora Pagan , Vincenzo Bagnardi , Tommaso De Pas , Paola Queirolo , Elisabetta Pennacchioli , Chiara Catania , Emilia Cocorocchio , Pier Francesco Ferrucci , Maristella Saponara , Gianmarco Orsolini , Paola Zagami , Eleonora Nicoló , Filippo De Marinis , Giampaolo Tortora , Emilio Bria , Saverio Minucci , Hadine Joffe, Paolo Veronesi 10, Jennifer Wargo, Rachel Rosenthal , Charles Swanton, Alberto Mantovani , Richard D Gelber, Giuseppe Viale, Aron Goldhirsch , Giuseppe Giaccone
Clin Cancer Res 2021 Aug 1;27(15):4311-4324.
https://pubmed.ncbi.nlm.nih.gov/34016641/
01/08/2021
Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges
Ulrich B, Pradines A, Mazieres J, Guibert N.
Cancers(Basel). 2021;13(15).
26/07/2021
An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma
Watts, C. Ashkan, K. Jenkinson, M. D. Price, S. J. Santarius, T. Matys, T. Zhang, T. T. Finch, A. Collins, P. Allinson, K. Jefferies, S. J. Scoffings, D. J. Zisakis, A. Phillips, M. Wanek, K. Smith, P. Clifton-Hadley, L. Counsell, N.
https://www.ncbi.nlm.nih.gov/pubmed/34209555
29/06/2021
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients
Biasco, L. Izotova, N. Rivat, C. Ghorashian, S. Richardson, R. Guvenel, A. Hough, R. Wynn, R. Popova, B. Lopes, A. Pule, M. Thrasher, A. J. Amrolia, P. J
https://www.ncbi.nlm.nih.gov/pubmed/34345830
01/06/2021
: Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
Kurtz, J. E., Gebski, V., Sukhin, V., Carey, M., Kong, I., Glasspool, R. M., Berek, J. S., de Paiva Batista, M., Hall, M., Kim, J. W., Yeoshoua, E., Fujiwara, N., Nam, B. H., Polleis, S., Lee, J. Y., Strojna, A., Farrelly, L., Schwameis, R., Fossati, R., Darlington, A. S., Lai, C. H., Wright, A. A., Rosenblat, O., Harter, P., Roxburgh, P., Chowdhury, R. R., Chang, T. C., Paoletti, X., Friedlander, M. and Gynecologic Cancer InterGroup symptom benefit, committee
Gynecol Oncol. 2021 May;161(2):502-507. 
https://www.ncbi.nlm.nih.gov/pubmed/33612336
01/05/2021
Monitoring advances including consent: learning from COVID-19 trials and other trials running in UKCRC registered clinical trials units during the pandemic
Love, S. B. Armstrong, E. Bayliss, C. Boulter, M. Fox, L. Grumett, J. Rafferty, P. Temesi, B. Wills, K. Corkhill, A.
https://www.ncbi.nlm.nih.gov/pubmed/33853635
14/04/2021
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial
Russell, J. Collins, A. Fowler, A. Karanth, M. Saha, C. Docherty, S. Padayatty, J. Maw, K. Lentell, I. Cooke, L. Hodson, A. Shah, N. Sadullah, S. Grigoropoulos, N. Qian, W. Kirkwood, A. A. Uttenthal, B. J. Johnson, P. Follows, G. A.
https://www.ncbi.nlm.nih.gov/pubmed/33641019
01/04/2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
Ledermann, J. A., Embleton-Thirsk, A. C., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., Gonzalez-Martin, A., Deane, E., Popoola, B., Farrelly, L., Swart, A. M., Kaplan, R. S., Parmar, M. K. B. and collaborators, Icon
ESMO Open. 2021 Apr;6(2):100043.
 https://www.ncbi.nlm.nih.gov/pubmed/33610123
01/04/2021
Tracking Cancer Evolution through the Disease Course
Chris Bailey, James RM. Black, James L. Reading, Kevin Litchfield, Samra Turajlic,Nicholas McGranahan, Mariam Jamal-Hanjani, and Charles Swanton

Cancer Discov. 2021 Apr 1; 11(4): 916–932.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7611362/ 
01/04/2021
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial
Post, C. C. B. de Boer, S. M. Powell, M. E. Mileshkin, L. Katsaros, D. Bessette, P. Haie-Meder, C. Ottevanger, N. P. B. Ledermann, J. A. Khaw, P. D'Amico, R. Fyles, A. Baron, M. H. Kitchener, H. C. Nijman, H. W. Lutgens, Lchw Brooks, S. Jurgenliemk-Schulz, I. M. Feeney, A. Goss, G. Fossati, R. Ghatage, P. Leary, A. Do, V. Lissoni, A. A. McCormack, M. Nout, R. A. Verhoeven-Adema, K. W. Smit, Vthbm Putter, H. Creutzberg, C. L.
https://www.ncbi.nlm.nih.gov/pubmed/33129910
15/03/2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial
Popat, R. Counsell, N. de Tute, R. De-Silva, D. Phillips, E. H. Cavenagh, J. D. Adedayo, T. Braganca, N. Roddie, C. Streetly, M. Schey, S. Koh, M. B. C. Crowe, J. Morris, T. C. Cook, G. Smith, P. Clifton-Hadley, L. Rabin, N. Owen, R. Yong, K. Padimac investigators
https://www.ncbi.nlm.nih.gov/pubmed/33715154
14/03/2021
Course of symptoms for loss of sense of smell and taste over time in one thousand forty-one healthcare workers during the Covid-19 pandemic: Our experience
Lechner, M. Liu, J. Counsell, N. Ta, N. H. Rocke, J. Anmolsingh, R. Eynon-Lewis, N. Paun, S. Hopkins, C. Khwaja, S. Kumar, B. N. Jayaraj, S. Lund, V. J. Philpott, C.
https://www.ncbi.nlm.nih.gov/pubmed/33283459
01/03/2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
Camilleri, M. Cuadrado, M. Phillips, E. Wilson, W. Jenner, R. Pang, G. Kamora, S. Streetly, M. Popat, R. Bygrave, C. Owen, R. Cavenagh, J. Chapman, M. Sive, J. Eccersley, L. Sheaff, M. Benjamin, R. Ramasamy, K. Cook, G. Virchis, A. Chavda, S. J. Clifton-Hadley, L. Scully, M. A. Yong, K.
https://www.ncbi.nlm.nih.gov/pubmed/33650100
01/03/2021
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial
Hoskin, P. Popova, B. Schofield, O. Brammer, C. Robinson, M. Brunt, A. M. Madhavan, K. Illidge, T. Gallop-Evans, E. Syndikus, I. Clifton-Hadley, L. Kirkwood, A. A.
https://www.ncbi.nlm.nih.gov/pubmed/33539729
01/03/2021
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial
Gleeson, M. Counsell, N. Cunningham, D. Lawrie, A. Clifton-Hadley, L. Hawkes, E. McMillan, A. Ardeshna, K. M. Burton, C. Chadwick, N. Gambell, J. Smith, P. Mouncey, P. Pocock, C. Radford, J. Davies, J. Turner, D. Kruger, A. Johnson, P. Linch, D.
https://www.ncbi.nlm.nih.gov/pubmed/32436212
01/03/2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients
McCulloch, R. Lewis, D. Crosbie, N. Eyre, T. A. Bolam, S. Arasaretnam, A. Creasey, T. Goradia, H. McMillan, A. Dawi, S. Harrison, S. Miles, O. Robinson, A. Dutton, D. Wilson, M. R. McKay, P. Follows, G. Phillips, N. Patmore, R. Lambert, J. Bishton, M. Osborne, W. Johnston, R. Kirkwood, A. A. Rule, S.
https://www.ncbi.nlm.nih.gov/pubmed/33620106
23/02/2021
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
Kurtz, J. E. Gebski, V. Sukhin, V. Carey, M. Kong, I. Glasspool, R. M. Berek, J. S. de Paiva Batista, M. Hall, M. Kim, J. W. Yeoshoua, E. Fujiwara, N. Nam, B. H. Polleis, S. Lee, J. Y. Strojna, A. Farrelly, L. Schwameis, R. Fossati, R. Darlington, A. S. Lai, C. H. Wright, A. A. Rosenblat, O. Harter, P. Roxburgh, P. Chowdhury, R. R. Chang, T. C. Paoletti, X. Friedlander, M. Gynecologic Cancer InterGroup symptom benefit, committee
https://www.ncbi.nlm.nih.gov/pubmed/33612336
18/02/2021
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation
Ainley, L. Chavda, S. J. Counsell, N. Cheesman, S. Newrick, F. Horder, J. Kyriakou, C. Papanikolaou, X. Sive, J. Lee, L. Wechalekar, A. Mehta, A. Popat, R. Rabin, N. Yong, K.
https://www.ncbi.nlm.nih.gov/pubmed/33236352
02/02/2021
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study
Mikhaeel, N. G. Cunningham, D. Counsell, N. McMillan, A. Radford, J. A. Ardeshna, K. M. Lawrie, A. Smith, P. Clifton-Hadley, L. O'Doherty, M. J. Barrington, S. F.
https://www.ncbi.nlm.nih.gov/pubmed/32621535
01/02/2021
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Elyashiv, O. Ledermann, J. Parmar, G. Farrelly, L. Counsell, N. Feeney, A. El-Khouly, F. Macdonald, I. Neto, A. Arthur-Darkwa, E. Burnett, E. Jayson, G. C. Mileshkin, L. Gourley, C. Nicum, S.
https://www.ncbi.nlm.nih.gov/pubmed/33097567
01/01/2021
Transcriptome analysis of IPF fibroblastic foci identifies key pathways involved in fibrogenesis
Guillotin, D. Taylor, A. R. Plate, M. Mercer, P. F. Edwards, L. M. Haggart, R. Miele, G. McAnulty, R. J. Maher, T. M. Hynds, R. E. Jamal-Hanjani, M. Marshall, R. P. Fisher, A. J. Blanchard, A. D. Chambers, R. C.
Thorax 2021 Jan;76(1):73-82
https://www.ncbi.nlm.nih.gov/pubmed/33214245

https://thorax.bmj.com/content/thoraxjnl/76/1/73.full.pdf
01/01/2021
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial
Camilleri, M. Sive, J. Wilson, W. Pang, G. Jenner, R. Phillips, E. Popat, R. Ramasamy, K. Bygrave, C. Dadaga, T. Streetly, M. Cavenagh, J. Chapman, M. Barrington, S. Pike, L. Owen, R. Clifton-Hadley, L. Yong, K.
https://www.ncbi.nlm.nih.gov/pubmed/33222153
01/01/2021
Publications in 2020
PyClone-VI: scalable inference of clonal population structures using whole genome data
Gillis S, Roth A.
BMCBioinformatics. 2020;21(1):571.
10/12/2020
Revealing the subtyping of non-small cell lung cancer based on genomic evolutionary patterns by multi-region sequencing
Liao G, Liang X, Ping Y, Zhang Y, Liao J, Wang Y, et al.
CancerMed. 2020;9(24):9485-98.
01/12/2020
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion
Moorman, A. V., Schwab, C., Winterman, E., Hancock, J., Castleton, A., Cummins, M., Gibson, B., Goulden, N., Kearns, P., James, B., Kirkwood, A. A., Lancaster, D., Madi, M., McMillan, A., Motwani, J., Norton, A., O'Marcaigh, A., Patrick, K., Bhatnagar, N., Qureshi, A., Richardson, D., Stokley, S., Taylor, G., van Delft, F. W., Moppett, J., Harrison, C. J., Samarasinghe, S. and Vora, A.
https://www.ncbi.nlm.nih.gov/pubmed/32926422
01/12/2020
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
Hall, M. R., Dehbi, H. M., Banerjee, S., Lord, R., Clamp, A., Ledermann, J. A., Nicum, S., Lilleywhite, R., Bowen, R., Michael, A., Feeney, A., Glasspool, R., Hackshaw, A. and Rustin, G.
https://www.ncbi.nlm.nih.gov/pubmed/33077258
01/12/2020
Pervasive chromosomal instability and karyotype order in tumour evolution.
Watkins TBK, Lim EL, Petkovic M, Elizalde S, Birkbak NJ, Wilson GA, et al.
Nature.2020;587(7832):126-32.
01/11/2020
Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs
Glynne-Jones, R., Meadows, H. M., Lopes, A., Muirhead, R., Sebag-Montefiore, D. and Adams, R.

Annals of oncology. 2020;31(11):1587-1588.

https://www.ncbi.nlm.nih.gov/pubmed/32822831
01/11/2020
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'
Fox, T. A., Troy-Barnes, E., Kirkwood, A. A., Chan, W. Y., Day, J. W., Chavda, S. J., Kumar, E. A., David, K., Tomkins, O., Sanchez, E., Scully, M., Khwaja, A., Lambert, J., Singer, M., Roddie, C., Morris, E. C., Yong, K. L., Thomson, K. J. and Ardeshna, K. M.
https://www.ncbi.nlm.nih.gov/pubmed/33103782
01/11/2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Leon-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, Vthbm, Edmondson, R. J., Putter, H., Kitchener, H. C., Crosbie, E. J., de Bruyn, M., Nout, R. A., Horeweg, N., Creutzberg, C. L., Bosse, T. and Trans, Portec consortium
https://www.ncbi.nlm.nih.gov/pubmed/32749941
10/10/2020
Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial
Glynne-Jones, R., Meadows, H. M., Lopes, A., Muirhead, R., Sebag-Montefiore, D., Adams, R. and group, Actii study

Ann Oncol. 2020 Oct;31(10):1376-1385.

https://www.ncbi.nlm.nih.gov/pubmed/32619648
01/10/2020
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy
Fox, T. A., Troy-Barnes, E., Kirkwood, A. A., Chan, W. Y., Day, J. W., Chavda, S. J., Kumar, E. A., David, K., Tomkins, O., Sanchez, E., Scully, M., Khwaja, A., Lambert, J., Singer, M., Roddie, C., Morris, E. C., Yong, K. L., Thomson, K. J. and Ardeshna, K. M.

https://www.ncbi.nlm.nih.gov/pubmed/32678948
01/10/2020
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca AU, et al.
CancerDiscov. 2020;10(10):1489-99.
01/10/2020
Delivering low-dose CT screening for lung cancer: a pragmatic approach.
Horst C, Dickson JL, Tisi S, Ruparel M, Nair A, Devaraj A, et al.
Thorax.2020;75(10):831-2.
01/10/2020
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Booth, S., Plaschkes, H., Kirkwood, A. A., Gibb, A., Horgan, P., Higham, C., Oladipo, J. M., Browning, J., Khan, U., Tseu, B., Chen, L., Willan, J., Wolf, J., Gunawan, A., Fields, P., Ebsworth, T., Lown, R., Gordon-Walker, D., Shah, N., Linton, K. M., Collins, G. P., Kothari, J., Hildyard, C. and Eyre, T. A.

https://www.ncbi.nlm.nih.gov/pubmed/32915975
22/09/2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
Enkhtsetseg Munkhbaatar, Michelle Dietzen, Deepti Agrawal, Martina Anton, Moritz Jesinghaus, Melanie Boxberg, Nicole Pfarr, Pidassa Bidola, Sebastian Uhrig, Ulrike Höckendorf, Anna-Lena Meinhardt, Adam Wahida, Irina Heid, Rickmer Braren, Ritu Mishra, Arne Warth, Thomas Muley, Patrina S. P. Poh, Xin Wang, Stefan Fröhling, Katja Steiger, Julia Slotta-Huspenina, Martijn van Griensven, Franz Pfeiffer, Sebastian Lange, Roland Rad, Magda Spella, Georgios T. Stathopoulos, Jürgen Ruland, Florian Bassermann, Wilko Weichert, Andreas Strasser, Caterina Branca, Mathias Heikenwalder, Charles Swanton, Nicholas McGranahan & Philipp J. Jost

Nature Communications volume 11, Article number: 4527 (2020)

https://www.nature.com/articles/s41467-020-18372-1
10/09/2020
Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations
Gewandter, J. S., Dworkin, R. H., Turk, D. C., Devine, E. G., Hewitt, D., Jensen, M. P., Katz, N. P., Kirkwood, A. A., Malamut, R., Markman, J. D., Vrijens, B., Burke, L., Campbell, J. N., Carr, D. B., Conaghan, P. G., Cowan, P., Doyle, M. K., Edwards, R. R., Evans, S. R., Farrar, J. T., Freeman, R., Gilron, I., Juge, D., Kerns, R. D., Kopecky, E. A., McDermott, M. P., Niebler, G., Patel, K. V., Rauck, R., Rice, A. S. C., Rowbotham, M., Sessler, N. E., Simon, L. S., Singla, N., Skljarevski, V., Tockarshewsky, T., Vanhove, G. F., Wasan, A. D. and Witter, J.
https://www.ncbi.nlm.nih.gov/pubmed/31843583
01/09/2020
Reply to Comment(s) on "Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort"
Hutchison, I. and Hackshaw, A.
https://www.ncbi.nlm.nih.gov/pubmed/32669675
01/09/2020
Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial
McMillan, A. K., Phillips, E. H., Kirkwood, A. A., Barrans, S., Burton, C., Rule, S., Patmore, R., Pettengell, R., Ardeshna, K. M., Lawrie, A., Montoto, S., Paneesha, S., Clifton-Hadley, L. and Linch, D. C.
https://www.ncbi.nlm.nih.gov/pubmed/32464282
01/09/2020
Anosmia and hyposmia in health-care workers with undiagnosed SARS-CoV-2 infection.
Lechner M, Counsell N, Liu J, Eynon-Lewis N, Paun S, Lund VJ, et al.

Lancet Microbe. 2020;1(4):e150.  

https://www.ncbi.nlm.nih.gov/pubmed/33521715

01/08/2020
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival
Bishton, M. J., Rule, S., Wilson, W., Turner, D., Patmore, R., Clifton-Hadley, L., McMillan, A., Lush, R. and Haynes, A.
Br J Haematol. 2020;190(4):545-54.

https://www.ncbi.nlm.nih.gov/pubmed/32150649
01/08/2020
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality
Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., Boeing, S., Krzystanek, M., Djureinovic, D., La Fleur, L., Greco, M., Dome, B., Fillinger, J., Brunnstrom, H., Wu, Y., Moore, D. A., Skrzypski, M., Abbosh, C., Litchfield, K., Al Bakir, M., Watkins, T. B. K., Veeriah, S., Wilson, G. A., Jamal-Hanjani, M., Moldvay, J., Botling, J., Chinnaiyan, A. M., Micke, P., Hackshaw, A., Bartek, J., Csabai, I., Szallasi, Z., Herrero, J., McGranahan, N., Swanton, C. and Consortium, T. RACERx
https://www.ncbi.nlm.nih.gov/pubmed/32494065
01/07/2020
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
Fennell, D. A., Danson, S., Woll, P. J., Forster, M., Talbot, D., Child, J., Farrelly, L., Sharkey, A., Busacca, S., Ngai, Y., Hackshaw, A. and Wheeler, G. M.
Clin Cancer Res. 2020 Sep 15;26(18):4748-4755. 
https://www.ncbi.nlm.nih.gov/pubmed/32669375
01/07/2020
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5)treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRItrial
Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrons, Anthony Lawrie, Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton-Hadley, David C. Linch, Andrew K. McMillan

Journal: eJHaem

Volume: Volume1, Issue: 1.  Pages:133-141
01/07/2020
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., Zhou, C., Wilson, G. A., Jamal-Hanjani, M., Birkbak, N., Pierce, J., Kim, C. S., Ferdous, S., Burt, D. J., Slane-Tan, D., Gomes, F., Moore, D., Shah, R., Al Bakir, M., Hiley, C., Veeriah, S., Summers, Y., Crosbie, P., Ward, S., Mesquita, B., Dynowski, M., Biswas, D., Tugwood, J., Blackhall, F., Miller, C., Hackshaw, A., Brady, G., Swanton, C., Dive, C. and Consortium, T. RACERx
https://www.ncbi.nlm.nih.gov/pubmed/32494064
01/07/2020
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
Khalid AbdulJabbar, Shan E. Ahmed Raza, Rachel Rosenthal, Mariam Jamal-Hanjani, Selvaraju Veeriah, Ayse Akarca, Tom Lund, David A. Moore, Roberto Salgado, Maise Al Bakir, Luis Zapata, Crispin T. Hiley, Leah Officer, Marco Sereno, Claire Rachel Smith, ShereneLoi, Allan Hackshaw, Teresa Marafioti, Sergio A. Quezada, Nicholas McGranahan, John Le Quesne, TRACERx Consortium, Charles Swanton & Yinyin Yuan
Nat Med. 2020 July 01; 26(7): 1054–1062
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610840/pdf/EMS124252.pdf
01/07/2020
Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer
Rusi Zhang, Xuewen Zhang, Zirui Huang, Fang Wang, Yongbin Lin, Yingsheng Wen, Li Liu, Jinbo Li, Xinyi Liu5 , Wenzhuan Xie , Mengli Huang , Gongming Wang, Longjun Yang, Dechang Zhao, Xiangyang Yu , Kexing Xi , Weidong Wang , Ling Cai, Lanjun Zhang
Transl Lung Cancer Res 2020;9(3):722-730
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354122/pdf/tlcr-09-03-722.pdf
01/06/2020
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development
Concin, N., Ray-Coquard, I., Glasspool, R. M., Braicu, E., Farrelly, L., Votan, B., Mirza, M. R., Gonzalez Martin, A., Vergote, I. and Pignata, S.
https://www.ncbi.nlm.nih.gov/pubmed/32404377
01/06/2020
A review of available software for adaptive clinical trial design
Grayling, M. J. and Wheeler, G. M.
https://www.ncbi.nlm.nih.gov/pubmed/32063024
01/06/2020
Where do we go from here? - Opportunities and barriers to the career development of trial managers: a survey of UK-based trial management professionals
Mitchell, E., Goodman, K., Hartley, S., Hickey, H., McDonald, A. M., Meadows, H. M., Rhodes, S., Taylor, J., Wakefield, N., Farrell, B. and Group, U. K. Trial Managers' Network Executive
https://www.ncbi.nlm.nih.gov/pubmed/32375851
06/05/2020
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Litchfield K, Stanislaw S, Spain L, Gallegos LL, Rowan A, Schnidrig D, Rosenbaum H, Harle A, Au L, Hill SM, Tippu Z, Thomas J, Thompson L, Xu H, Horswell S, Barhoumi A, Jones C, Leith KF, Burgess DL, Watkins TBK, Lim E, Birkbak NJ, Lamy P, Nordentoft I, Dyrskjøt L, Pickering L, Hazell S, Jamal-Hanjani M; PEACE Consortium, Larkin J, Swanton C, Alexander NR, Turajlic S
Cell Rep. 2020 May 5;31(5):107550.
https://pubmed.ncbi.nlm.nih.gov/32375028/
05/05/2020
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Ehsan Ghorani, James L. Reading, Jake Y. Henry, Marc Robert de Massy, Kroopa Joshi, Assma Ben Aissa, Andrew Georgiou, Mariana Werner Sunderland, Yien Ning Sophia Wong, Maria Vila De Mucha, William Day, Felipe Galvez-Cancino, Pablo D. Becker, Karl S. Peggs, Karl S. Peggs, Andrew Georgiou, Mariana Werner Sunderland, James L. Reading, Sergio A. Quezada, Ehsan Ghorani, Marc Robert de Massy & Sergio A. Quezada
Nat Cancer 1, 546–561 (2020).
https://pubmed.ncbi.nlm.nih.gov/32803172/
01/05/2020
Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial
Brazil, L., Swampillai, A. L., Mak, K. M., Edwards, D., Mesiri, P., Clifton-Hadley, L., Shaffer, R., Lewis, J., Watts, C., Jeffries, S., Gkogkou, P., Chalmers, A. J., Fersht, N. L., Hackshaw, A. and Short, S. C.
https://www.ncbi.nlm.nih.gov/pubmed/32642699
27/04/2020
Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study
Phillips, E. H., Lannon, M. M., Lopes, A., Chadwick, H., Jones, G., Sieniawski, M., Davies, A., Wood, K., Clifton-Hadley, L., Smith, P., Lawrie, A., Chadwick, N. and Lennard, A. L.
https://www.ncbi.nlm.nih.gov/pubmed/30862820
01/04/2020
Designing and evaluating dose-escalation studies made easy: The MoDEsT web app
Pallmann, P., Wan, F., Mander, A. P., Wheeler, G. M., Yap, C., Clive, S., Hampson, L. V. and Jaki, T.
https://www.ncbi.nlm.nih.gov/pubmed/31856600
01/04/2020
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
Townsend, W., Leong, S., Hoskin, P., Diez, P., Patrick, P., Linch, D., Wong, W. L., Kayani, I., Sanghera, B., Lopes, A., Daw, S., Collins, G., Clifton-Hadley, L. and Ardeshna, K.
https://www.ncbi.nlm.nih.gov/pubmed/31710702
01/04/2020
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer
Fenwick, J. D., Landau, D. B., Baker, A. T., Bates, A. T., Eswar, C., Garcia-Alonso, A., Harden, S. V., Illsley, M. C., Laurence, V., Malik, Z., Mayles, W. P. M., Miles, E., Mohammed, N., Spicer, J., Wells, P., Vivekanandan, S., Mullin, A. M., Hughes, L., Farrelly, L., Ngai, Y. and Counsell, N.
Int J Radiat Oncol Biol Phys. 2020 Mar15;106(4):733-742. 
https://www.ncbi.nlm.nih.gov/pubmed/31809876
15/03/2020
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution
Saioa López, Emilia L. Lim, Stuart Horswell, Kerstin Haase, Ariana Huebner, Michelle Dietzen, Thanos P. Mourikis, Thomas B. K. Watkins, Andrew Rowan, Sally M. Dewhurst, Nicolai J. Birkbak, Gareth A. Wilson, Peter Van Loo, Mariam Jamal-Hanjani, TRACERx Consortium, Charles Swanton & Nicholas McGranahan
Nat Genet 52, 283–293 (2020)
https://doi.org/10.1038/s41588-020-0584-7
05/03/2020
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, et al

J Natl Cancer Inst. 2020 Feb 1;112(2):200-210.

https://www.ncbi.nlm.nih.gov/pubmed/31077311
01/02/2020
IMRiS phase II study of IMRT in limb sarcomas: Results of the pre-trial QA facility questionnaire and workshop
Simoes, R., Miles, E., Yang, H., Le Grange, F., Bhat, R., Forsyth, S. and Seddon, B.
https://www.ncbi.nlm.nih.gov/pubmed/31902458
01/02/2020
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
Lamarca, A., Ross, P., Wasan, H. S., Hubner, R. A., McNamara, M. G., Lopes, A., Manoharan, P., Palmer, D., Bridgewater, J. and Valle, J. W.
https://www.ncbi.nlm.nih.gov/pubmed/31077311
01/02/2020
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma
Illidge, T. M., Phillips, E. H., Counsell, N., Pettengell, R., Johnson, P. W. M., Culligan, D. J., Popova, B., Clifton-Hadley, L., McMillan, A., Hoskin, P., Barrington, S. F. and Radford, J.

https://www.ncbi.nlm.nih.gov/pubmed/31935289
14/01/2020
A Phase I/ II Feasibility Study of Intravenous Cetuximab in Combination with 5 days Weekly Oral Capecitabine and Preoperative Radiotherapy in Rectal Cancer (XERXES)
Glynne-Jones, R; Meadows, HM; Lopes, A; Riddle, P; Duggan, M; Sebag-Montefiore, D; McDonald, A; Samuel, L; Falk, S; Adams, R

Arch Clin Biomed Res 2020; 4 (4): 394-412

https://www.fortunejournals.com/articles/a-phase-i-ii-feasibility-study-of-intravenous-cetuximab-in-combination-with-5-days-weekly-oral-capecitabine-and-preoperative-radio.pdf
01/01/2020
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, et al
Journal of the National Cancer Institute. 2020;112(2):200-10.
01/01/2020
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma
Illidge TM, Phillips EH, Counsell N, Pettengell R, Johnson PWM, Culligan DJ, et al
Blood Adv. 2020;4(1):203-6.
01/01/2020
Publications in 2019
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.
Das-Gupta E, Thomson KJ, Bloor AJC, Clark AD, Mackinnon S, Kayani I, Clifton-Hadley L, Patrick P, El-Mehidi N, Lawrie A, Kirkwood AA, Russell NH, Linch DC, Peggs KS.
Blood Adv. 2019 Dec23;3(24):4264-4270. 
23/12/2019
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial
Hoskin, P. J., Hopkins, K., Misra, V., Holt, T., McMenemin, R., Dubois, D., McKinna, F., Foran, B., Madhavan, K., MacGregor, C., Bates, A., O'Rourke, N., Lester, J. F., Sevitt, T., Roos, D., Dixit, S., Brown, G., Arnott, S., Thomas, S. S., Forsyth, S., Beare, S., Reczko, K., Hackshaw, A. and Lopes, A.

https://www.ncbi.nlm.nih.gov/pubmed/31794625
03/12/2019
Reply to H.J.A. Adams et al and C. Kobe et al
Barrington, S. F., Phillips, E. H., Counsell, N. and Radford, J.
https://www.ncbi.nlm.nih.gov/pubmed/31566994
01/12/2019
How to design a dose-finding study using the continual reassessment method
Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, et al
BMC Med Res Methodol. 2019;19(1):18
01/12/2019
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
Townsend, W., Leong, S., Hoskin, P., Diez, P., Patrick, P., Linch, D., Wong, W. L., Kayani, I., Sanghera, B., Lopes, A., Daw, S., Collins, G., Clifton-Hadley, L. and Ardeshna, K.
https://www.ncbi.nlm.nih.gov/pubmed/31710702
11/11/2019
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
Rivin Del Campo, E., Matzinger, O., Haustermans, K., Peiffert, D., Glynne-Jones, R., Winter, K. A., Konski, A. A., Ajani, J. A., Bosset, J. F., Hannoun-Levi, J. M., Puyraveau, M., Chakravarthy, A. B., Meadows, H., Northover, J., Collette, L., Christiaens, M. and Maingon, P.
https://www.ncbi.nlm.nih.gov/pubmed/31574418
01/11/2019
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, et al
Nat Med. 2019 Oct;25(10):1534-1539. doi: 10.1038/s41591-019-0593-1.
25/10/2019
A clonal expression biomarker associates with lung cancer mortality
Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, et al
Nat Med. 2019 Oct;25(10):1540-1548. doi: 10.1038/s41591-019-0595-z.
25/10/2019
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, et al.
Nat Med. 2019 Oct;25(10):1549-1559. doi: 10.1038/s41591-019-0592-2.
https://www.ncbi.nlm.nih.gov/pubmed/31591606
25/10/2019
Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
Burt R, Dey A, Aref S, Aguiar M, Akarca A, Bailey K, Day W, Hooper S, Kirkwood A, Kirschner K, Lee SW, Lo Celso C, Manji J, Mansour MR, Marafioti T, Mitchell RJ, Muirhead RC, Cheuk Yan Ng K, Pospori C, Puccio I, Zuborne-Alapi K, Sahai E, Fielding AK.

https://www.ncbi.nlm.nih.gov/pubmed/31501154

24/10/2019
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application
Embleton-Thirsk, A., Deane, E., Townsend, S., Farrelly, L., Popoola, B., Parker, J., Rustin, G., Sydes, M., Parmar, M., Ledermann, J. and Kaplan, R.
https://www.ncbi.nlm.nih.gov/pubmed/31347385
16/10/2019
P1.11-19 Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test
S.Janes, J.Dickson, A.Devaraj, C.Horst, S.Quaife, C.Levermore, K.Gyertson, A.Mullin, L.Farrelly, B.Allen, N.Zhang, C.Clarke, S.Hamilton, A.Hartman, A.Hackshaw
https://www.jto.org/article/S1556-0864(19)31775-7/fulltext#relatedArticles
02/10/2019
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies.
Beaton L, Tregidgo HFJ, Znati SA, Forsyth S, Clarkson M et al.
JMIR Res Protoc 2019| vol. 8 | iss. 10 | e13696
https://www.ncbi.nlm.nih.gov/pubmed/31579027
02/10/2019
A Clonal Expression Biomarker Refines Survival Forecasting in Lung Cancer
Biswas, D., Birkbak, N.J., Rosenthal, R. et al.
Nat Med 25, 1540–1548 (2019) doi:10.1038/s41591-019-0595-z
https://www.nature.com/articles/s41591-019-0595-z.pdf?proof=t+target%3D
01/10/2019
Pulmonary venous tumour cells disseminating prior to tumour resection are heterogeneous, predictive of relapse and future metastasis: TRACERx Lung
Chemi, F., Rothwell, D.G., McGranahan, N. et al.
Nat Med 25, 1534–1539 (2019) doi:10.1038/s41591-019-0593-1
https://www.ncbi.nlm.nih.gov/pubmed/31591595
01/10/2019
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity
Eyre, T. A., Kirkwood, A. A., Wolf, J., Hildyard, C., Mercer, C., Plaschkes, H., Griffith, J., Fields, P., Gunawan, A., Oliver, R., Booth, S., Martinez-Calle, N., McMillan, A., Bishton, M., Fox, C. P., Collins, G. P. and Hatton, C. S. R.
https://www.ncbi.nlm.nih.gov/pubmed/31222719
01/10/2019
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., D'Amico, R., Fyles, A., Baron, M. H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Gribaudo, S., Provencher, D., Hanzen, C., Kruitwagen, R. F., Smit, Vthbm, Singh, N., Do, V., Lissoni, A., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., Creutzberg, C. L. and Group, Portec Study

https://www.ncbi.nlm.nih.gov/pubmed/31345626
20/09/2019
A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era
Eyre, T. A., Djebbari, F., Kirkwood, A. A. and Collins, G. P.
https://www.ncbi.nlm.nih.gov/pubmed/31488560
05/09/2019
Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial
Phillips, E. H., Devereux, S., Radford, J., Mir, N., Adedayo, T., Clifton-Hadley, L. and Johnson, R.
https://www.ncbi.nlm.nih.gov/pubmed/30773077
01/09/2019
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian, Anne Marijn Kramer, Shimobi Onuoha, Gary Wright, Jack Bartram, Rachel Richardson, Sarah J. Albon, Joan Casanovas-Company, Fernanda Castro, Bilyana Popova, Krystle Villanueva, Jenny Yeung, Winston Vetharoy, Aleks Guvenel, Patrycja A. Wawrzyniecka, Leila Mekkaoui, Gordon Weng-Kit Cheung, Danielle Pinner, Jan Chu, Giovanna Lucchini, Juliana Silva, Oana Ciocarlie, Arina Lazareva, Sarah Inglott, Kimberly C. Gilmour, Gulrukh Ahsan, Mathieu Ferrari, Somayya Manzoor, Kim Champion, Tony Brooks, Andre Lopes, Allan Hackshaw, Farzin Farzaneh, Robert Chiesa, Kanchan Rao, Denise Bonney, Sujith Samarasinghe, Nicholas Goulden, Ajay Vora, Paul Veys, Rachael Hough, Robert Wynn, Martin A. Pule & Persis J. AmroliaE

Nat Med 2019 Sep;25(9):1408-1414.

https://www.ncbi.nlm.nih.gov/pubmed/31477906
01/09/2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study
Barrington, S. F., Phillips, E. H., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Townsend, W., Culligan, D., Popova, B., Clifton-Hadley, L., McMillan, A., Hoskin, P., O'Doherty, M. J., Illidge, T. and Radford, J.
https://www.ncbi.nlm.nih.gov/pubmed/31112475
10/07/2019
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.
Taylor SA, Mallett S, Ball S, Beare S, Bhatnagar G, Blunt D et al.
LancetGastroenterology & Hepatology 2019; 4: 529–37.
01/07/2019
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study
O'Reilly, M. A., Govender, D., Kirkwood, A. A., Vora, A., Samarasinghe, S., Khwaja, A., Grandage, V., Rao, A., Ancliff, P., Pavasovic, V., Cheng, D., Carpenter, B., Daw, S., Hough, R. and O'Connor, D.
https://www.ncbi.nlm.nih.gov/pubmed/30768682
01/07/2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
Gore, M., Hackshaw, A., Brady, W. E., Penson, R. T., Zaino, R., McCluggage, W. G., Ganesan, R., Wilkinson, N., Perren, T., Montes, A., Summers, J., Lord, R., Dark, G., Rustin, G., Mackean, M., Reed, N., Kehoe, S., Frumovitz, M., Christensen, H., Feeney, A., Ledermann, J. and Gershenson, D. M.
https://www.ncbi.nlm.nih.gov/pubmed/31005287
01/06/2019
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse
Cohen, O. C., Counsell, N., Rabin, N., Popat, R., Owen, R. G., Popova, B., Schofield, O., Clifton-Hadley, L., Lyons-Lewis, J., Rawstron, A., Spence, C., de Tute, R. M., Hughes, D., Moore, S., Smith, P. and Yong, K. L.
https://www.ncbi.nlm.nih.gov/pubmed/30460696
01/06/2019
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.
Taylor SA, Mallett S, Ball S, Beare S, Bhatnagar G, Bhowmik A et al.
Lancet RespiratoryMedicine. 2019; 7: 523–32.
01/06/2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Mato, A. R., Roeker, L. E., Eyre, T. A., Nabhan, C., Lamanna, N., Hill, B. T., Brander, D. M., Barr, P. M., Lansigan, F., Cheson, B. D., Singavi, A. K., Yazdy, M. S., Shah, N. N., Allan, J. N., Bhavsar, E. B., Rhodes, J., Kennard, K., Schuster, S. J., Williams, A. M., Skarbnik, A. P., Goy, A. H., Goodfriend, J. M., Dorsey, C., Coombs, C. C., Tuncer, H., Ujjani, C. S., Jacobs, R., Winter, A. M., Pagel, J. M., Bailey, N., Schuh, A., Shadman, M., Sitlinger, A., Weissbrot, H., Muralikrishnan, S., Zelenetz, A., Kirkwood, A. A. and Fox, C. P.
https://www.ncbi.nlm.nih.gov/pubmed/31101647
28/05/2019
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial
Stuart A Taylor, Sue Mallett, Sandy Beare, Gauraang Bhatnagar, Dominic Blunt, Peter Boavida, John Bridgewater, Caroline S Clarke, Marian Duggan, Steve Ellis, Robert Glynne-Jones, Vicky Goh, Ashley M Groves, Ayshea Hameeduddin, Sam M Janes, Edward W Johnston, Dow-Mu Koh, Anne Miles, Stephen Morris, Alison Morton, Neal Navani, John O’Donohue, Alfred Oliver, Anwar R Padhani, Helen Pardoe, Uday Patel, Shonit Punwani, Laura Quinn, Hameed Rafiee, Krystyna Reczko, Andrea G Rockall, Khawaja Shahabuddin, Harbir S Sidhu, Jonathan Teague, Mohamed A Thaha, Matthew Train, Katherine van Ree, Sanjaya Wijeyekoon, Steve Halligan, on behalf of the Streamline investigators*
Lancet Gastroenterol Hepatol 2019 Published Online May 9, 2019 http://dx.doi.org/10.1016/S2468-1253(19)30056-1 See Online/Commenthttp://dx.doi.org/10.1016/S2468-1253(19)30092-5
09/05/2019
Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial
Stuart A Taylor, Sue Mallett, Simon Ball, Sandy Beare, Gauraang Bhatnagar, Angshu Bhowmik, Peter Boavida, John Bridgewater, Caroline S Clarke, Marian Duggan, Steve Ellis, Robert Glynne-Jones, Vicky Goh, Ashley M Groves, Ayshea Hameeduddin, Sam M Janes, Edward W Johnston, Dow-Mu Koh, Sara Lock, Anne Miles, Stephen Morris, Alison Morton, Neal Navani, Alfred Oliver, Terry O’Shaughnessy, Anwar R Padhani, David Prezzi, Shonit Punwani, Laura Quinn, Hameed Rafiee, Krystyna Reczko, Andrea G Rockall, Peter Russell, Harbir S Sidhu, Nicola Strickland, Kathryn Tarver, Jonathan Teague, Steve Halligan, on behalf of the Streamline investigators*
Lancet Respir Med 2019 Published Online May 9, 2019 http://dx.doi.org/10.1016/ S2213-2600(19)30090-6 See Online/Comment http://dx.doi.org/10.1016/ S2213-2600(19)30081-5
09/05/2019
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
Eyre, T. A., Kirkwood, A. A., Gohill, S., Follows, G., Walewska, R., Walter, H., Cross, M., Forconi, F., Shah, N., Chasty, R., Hart, A., Broom, A., Marr, H., Patten, P. E. M., Dann, A., Arumainathan, A., Munir, T., Shankara, P., Bloor, A., Johnston, R., Orchard, K., Schuh, A. H., Fox, C. P. and the, U. K. C. L. L. Forum
https://www.ncbi.nlm.nih.gov/pubmed/30768675
01/05/2019
Sacroiliac Joint Ankylosis in Young Spondyloarthritis Patients Receiving Biologic Therapy: Observation of Serial Magnetic Resonance Imaging Scans
Bray, T. J. P., Lopes, A., Fisher, C., Ciurtin, C., Sen, D. and Hall-Craggs, M. A.

https://www.ncbi.nlm.nih.gov/pubmed/30295426
01/04/2019
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1
Chavda SJ, Maciocia PM, Mesiri P, Counsell N, Kothari J, Bird A, et al.
BrJ Haematol. 2019;185(2):350-3.
01/04/2019
Neoantigen directed immune escape in lung cancer evolution.
Rachel Rosenthal1,2,3, Elizabeth Larose Cadieux*4, Roberto Salgado*5,6, Maise Al Bakir*3, David A. Moore*7, Crispin T. Hiley*1,3, Tom Lund*8, Miljana Tanić9, James L. Reading8,10, Kroopa Joshi8, Jake Y. Henry8,10, Ehsan Ghorani8,10, Gareth A. Wilson1,3, Nicolai J. Birkbak1,3, Mariam Jamal-Hanjani1, Selvaraju Veeriah1, Zoltan Szallasi11,12, Sherene Loi5, Matthew D. Hellmann13,14, Andrew Feber15, Benny Chain16,17, Javier Herrero2, Sergio Quezada8,9, Jonas Demeulemeester4,18, Peter Van Loo4,17, Stephan Beck9, Nicholas McGranahan1,19# and Charles Swanton1,3#, on behalf of the TRACERx consortium

Nature. March 20; .

https://www.nature.com/articles/s41586-019-1032-7
20/03/2019
Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions
Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D, Beane J, et al.
NatMed. 2019;25(3):517-25.
01/03/2019
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma
Rule, S., Cook, G., Russell, N. H., Hunter, A., Robinson, S., Morley, N., Sureda, A., Patrick, P., Clifton-Hadley, L., Adedayo, T., Kirkwood, A. and Peggs, K. S.
https://www.ncbi.nlm.nih.gov/pubmed/30560573
01/03/2019
Neoantigen-directed immune escape in lung cancer evolution
Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanic, M., Reading, J. L., Joshi, K., Henry, J. Y., Ghorani, E., Wilson, G. A., Birkbak, N. J., Jamal-Hanjani, M., Veeriah, S., Szallasi, Z., Loi, S., Hellmann, M. D., Feber, A., Chain, B., Herrero, J., Quezada, S. A., Demeulemeester, J., Van Loo, P., Beck, S., McGranahan, N., Swanton, C. and consortium, T. RACERx
https://www.ncbi.nlm.nih.gov/pubmed/30894752
01/03/2019
High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study
Phillips EH, Lannon MM, Lopes A, Chadwick H, Jones G, Sieniawski M, et al.
Bone Marrow Transplant. 2019 Mar;54(3):465-8.

https://www.ncbi.nlm.nih.gov/pubmed/30104718
01/03/2019
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al.
CancerCell. 2019;35(2):329.
11/02/2019
Early morphological response is significantly associated with, but does not accurately predict, relapse in teenagers and young adults aged 10-24 years with acute lymphoblastic leukaemia (ALL): results from UKALL2003.
Furness CL, Kirkwood A, Rowntree C, Vora A, Mitchell C, Samarasinghe S, et al.
BrJ Haematol. 2019;184(4):663-6.
01/02/2019
How to design a dose-finding study using the continual reassessment method
Wheeler, G. M., Mander, A. P., Bedding, A., Brock, K., Cornelius, V., Grieve, A. P., Jaki, T., Love, S. B., Odondi, L., Weir, C. J., Yap, C. and Bond, S. J.
https://www.ncbi.nlm.nih.gov/pubmed/30658575
18/01/2019
Whole Genome Doubling mitigates Muller’s Ratchet in Lung Cancer Evolution
López S, Lim E, Huebner A, Dietzen M, Mourikis T, Watkins TBK, et al.
bioRxiv preprint 2019. doi: https://doi.org/10.1101/513457 
07/01/2019
The mTORC1/4E-BP1 axis represents a critical signalling node during fibrogenesis
Woodcock, H.V., Eley, J.D., Guillotin, D., Platé, M., Nanthakumar, C.B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R.B., Taylor, A.R., Zinn, N., Forty, E.J., Redding, M., Hynds, R.E., Swanton, C., Karsdal, M., Maher, T.M., Bergamini, G., Marshall, R.P., Blanchard, A.D., Mercer, P.F., Chambers, R.C.
Nat. Commun. 10, 6 (2019).
https://www.ncbi.nlm.nih.gov/pubmed/30602778
02/01/2019
An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood.
Uddin I, Joshi K, Oakes T, Heather JM, Swanton C; TRACERx consortium, Chain B
In: López-Soto A., Folgueras A. (eds) Cancer Immunosurveillance. Methods in Molecular Biology, vol 1884. Humana Press, New York, NY 
https://www.ncbi.nlm.nih.gov/pubmed/30465193 
01/01/2019
Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including (18)F-FDG-PET-CT
Latifoltojar, A., Punwani, S., Lopes, A., Humphries, P. D., Klusmann, M., Menezes, L. J., Daw, S., Shankar, A., Neriman, D., Fitzke, H., Clifton-Hadley, L., Smith, P. and Taylor, S. A.
https://www.ncbi.nlm.nih.gov/pubmed/29948084
01/01/2019
449 Harmonization operations for global trials to overcome obstacles from 2004 – 2017: gynecologic cancer intergroup (GCIG)
Kajimoto Y, Bacon M, Stonebraker B, Votan B, Martyn J, Bryce J, et al.
International Journal of Gynecologic Cancer. 2019;29(Suppl 3):A184-A6.

https://ijgc.bmj.com/content/29/Suppl_3/A184.3.abstract
01/01/2019
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A.
Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51
01/01/2019
Publications in 2018
Novel CT-Based Objective Imaging Biomarkers of Long-Term Radiation-Induced Lung Damage
Veiga, C., Landau, D., Devaraj, A., Doel, T., White, J., Ngai, Y., Hawkes, D. J. and McClelland, J. R.

https://www.ncbi.nlm.nih.gov/pubmed/29908943
15/11/2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
Chapman, M. A., Sive, J., Ambrose, J., Roddie, C., Counsell, N., Lach, A., Abbasian, M., Popat, R., Cavenagh, J. D., Oakervee, H., Streetly, M. J., Schey, S., Koh, M., Willis, F., Virchis, A. E., Crowe, J., Quinn, M. F., Cook, G., Crawley, C. R., Pratt, G., Cook, M., Braganza, N., Adedayo, T., Smith, P., Clifton-Hadley, L., Owen, R. G., Sonneveld, P., Keats, J. J., Herrero, J. and Yong, K.
https://www.ncbi.nlm.nih.gov/pubmed/30181174
15/11/2018
Use of Two Self-referral Reminders and a Theory-Based Leaflet to Increase the Uptake of Flexible Sigmoidoscopy in the English Bowel Scope Screening Program: Results From a Randomized Controlled Trial in London
Kerrison RS, McGregor LM, Counsell N, Marshall S, Prentice A, Isitt J, et al.
Ann Behav Med. 2018;52(11):941-51.
22/10/2018
MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma
Fennell D, Danson S, Forster M, Talbot D, Woll P, Child J, et al.
Journalof Thoracic Oncology. 2018;13(10):S397.

https://doi.org/10.1016/j.jtho.2018.08.415
01/10/2018
BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC).
Glynne-Jones R, Hall MR, Lopes A, Pearce S, Goh V, Bosompem S, et al.
Heliyon.2018;4(9):e00804.
22/09/2018
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C, Birkbak NJ, Swanton C.
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. 
15/09/2018
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection
Abbosh C, Birkbak NJ, Swanton C
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586
15/09/2018
Genomic instability in mutant p53 cancer cells upon entotic engulfment
Mackay HL, Moore D, Hall C, Birkbak NJ, Jamal-Hanjani M, Karim SA, Phatak VM, Piñon L, Morton JP, Swanton C, Le Quesne J, Muller PAJ.
Nat Commun. 2018 Aug 3;9(1):3070.
03/08/2018
PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer.
Pereira SP, Jitlal M, Duggan M, Lawrie E, Beare S, O'Donoghue P, et al.
ESMOOpen. 2018;3(5):e000379.
23/07/2018
Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial.
Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, et al.
Haematologica. 2018;103(7):e288-e92.
01/07/2018
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia
Gohil, S. H., Maciocia, N., Patrick, P., Roberts, T., Counsell, N., Smith, P., Clifton-Hadley, L., Cwynarski, K., Pettitt, A. and Nathwani, A. C.
https://www.ncbi.nlm.nih.gov/pubmed/29164978
01/07/2018
Expansion of airway basal epithelial cells from primary human non-small cell lung cancer tumors
Hynds, R.E., Ben Aissa, A., Gowers, K.H.C., Watkins, T.B.K., Bosshard-Carter, L., Rowan, A.J., Veeriah, S., Wilson, G.A., Quezada, S.A., Swanton, C., TRACERx Consortium, Janes S.M.
Int J Cancer. 2018 Jul 1;143(1):160-166.
01/07/2018
Changes in circulating biomarkers in patients with advanced biliary tract cancer receiving cediranib or placebo plus cisplatin and gemcitabine in the UK ABC-03 trial
Backen A, Lopes A, Wasan H, Palmer D, Duggan M, Cunningham D, Anthoney A, Corrie P, Madhusudan S, Maraveyas A, Ross P, Justin W, Steward W, Rees C, McNamara M, Beare S, Bridgewater J, Dive C, Valle J

Br J Cancer. 2018 Jul;119(1):27-35.

https://pubmed.ncbi.nlm.nih.gov/29925934/
01/07/2018
Whole body functional and anatomical MRI: Accuracy in staging and interim response monitoring of Childhood and Adolescent Hodgkin’s Lymphoma compared to multimodality conventional imaging
Latifoltojar, A; Punwani, S; Lopes, A; Humphries, P; Neriman, D; Menezes, L; Daw, S; Shankar, A; Popova, B; Mak, KM; Fitzke, H; Smith, P; Clifton-Hadley, L; Taylor, S
Joint Annual Meeting ISMRM-ESMRMB.  ParisExpo Porte de Versailles, Paris, France, June 16-21 2018.
16/06/2018
Perceived patient burden and acceptability of whole body MRI for staging lung and colorectal cancer; comparison with standard staging investigations.
Evans RE, Taylor SA, Beare S, Halligan S, Morton A, Oliver A, et al.
BrJ Radiol. 2018;91(1086):20170731.
01/06/2018
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J. I., Nicol, D., O'Brien, T., Larkin, J., Horswell, S., Stares, M., Au, L., Jamal-Hanjani, M., Challacombe, B., Chandra, A., Hazell, S., Eichler-Jonsson, C., Soultati, A., Chowdhury, S., Rudman, S., Lynch, J., Fernando, A., Stamp, G., Nye, E., Jabbar, F., Spain, L., Lall, S., Guarch, R., Falzon, M., Proctor, I., Pickering, L., Gore, M., Watkins, T. B. K., Ward, S., Stewart, A., DiNatale, R., Becerra, M. F., Reznik, E., Hsieh, J. J., Richmond, T. A., Mayhew, G. F., Hill, S. M., McNally, C. D., Jones, C., Rosenbaum, H., Stanislaw, S., Burgess, D. L., Alexander, N. R., Swanton, C., Peace and Consortium, T. RACERx Renal
https://www.ncbi.nlm.nih.gov/pubmed/29656895
19/04/2018
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F et al.
Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.
18/04/2018
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, et al.
BMJOpen. 2018;8(4):e020690.
17/04/2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada
Cancer Cell. 2018 Apr 9;33(4):649-663.e4.
09/04/2018
Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92.
Whelan J, Hackshaw A, McTiernan A, Grimer R, Spooner D, Bate J, Ranft A, Paulussen M, Juergens H, Craft A, Lewis I
Clin Sarcoma Res. 2018;8:6. doi: 10.1186/s13569-018-0093-y
30/03/2018
Adjuvant therapy for women with high-risk endometrial carcinoma
Dowdy, S. C. and Glaser, G. E.
https://www.ncbi.nlm.nih.gov/pubmed/29449190
19/03/2018
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D., Hanzen, C., Lutgens, Lchw, Smit, Vthbm, Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., Creutzberg, C. L. and group, Portec study
https://www.ncbi.nlm.nih.gov/pubmed/29449189
19/03/2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
Forster M, Hackshaw A , De Pas T, Cobo M, Garrido P, Summers Y, Dingemans A-M, Flynn M, Schnell D, von Wangenheim U, Loembé A-B, Kaiser R, Lee SM
Lung Cancer 2018; 120:27-33
09/03/2018
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
Provencher, D. M., Gallagher, C. J., Parulekar, W. R., Ledermann, J. A., Armstrong, D. K., Brundage, M., Gourley, C., Romero, I., Gonzalez-Martin, A., Feeney, M., Bessette, P., Hall, M., Weberpals, J. I., Hall, G., Lau, S. K., Gauthier, P., Fung-Kee-Fung, M., Eisenhauer, E. A., Winch, C., Tu, D. and MacKay, H. J.
https://www.ncbi.nlm.nih.gov/pubmed/29186319
01/02/2018
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, et al
AnnOncol. 2018;29(2):424-30.
01/02/2018
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
King, M. T., Stockler, M. R., O'Connell, R. L., Buizen, L., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Bryce, J., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J. S., Sehouli, J., Feeney, A., Berton-Rigaud, D., Costa, D. S. J., Friedlander, M. L. and group, Gcig Symptom Benefit
https://www.ncbi.nlm.nih.gov/pubmed/29248998
27/01/2018
Chromosomal instability drives metastasis through a cytosolic DNA response
Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, et al.
Nature.2018;553(7689):467-72.
25/01/2018
Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports
Hackshaw A, Morris JK, Boniface S, Tang JL, Milenković D
BMJ. 2018;360:j5855. doi: 10.1136/bmj.j5855
24/01/2018
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma
Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS, et al.
AnnOncol. 2018;29(1):271-9.
01/01/2018
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)
Roncolato, F. T., Berton-Rigaud, D., O'Connell, R., Lanceley, A., Sehouli, J., Buizen, L., Okamoto, A., Aotani, E., Lorusso, D., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Hilpert, F., Ledermann, J. A., Kaminsky, M. C., Stockler, M. R., King, M. T. and Friedlander, M.
https://www.ncbi.nlm.nih.gov/pubmed/29107348
01/01/2018
Publications in 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, et al.

Nat Genet. 2017;49(12):1693-704.

https://pubmed.ncbi.nlm.nih.gov/29106415/
01/12/2017
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C; TRACERx Consortium.
Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub 2017 Oct 26.
30/11/2017
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C, TRACERx Consortium.
Cell. 2017 Nov 30;171(6):1259-1271.e11
30/11/2017
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
Berenjeno IM, Pineiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, et al.

Nat Commun. 2017;8(1):1773.

https://pubmed.ncbi.nlm.nih.gov/29170395/
24/11/2017
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: Significance of pre-treatment and post-resection RAS mutations
Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, et al.

Br J Cancer. 2017 Oct 24;117(9):1286-94.

https://pubmed.ncbi.nlm.nih.gov/28859058/
24/10/2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Seddon, B. Strauss, S. J. Whelan, J. Leahy, M. Woll, P. J. Cowie, F. Rothermundt, C. Wood, Z. Benson, C. Ali, N. Marples, M. Veal, G. J. Jamieson, D. Kuver, K. Tirabosco, R. Forsyth, S. Nash, S. Dehbi, H. M. Beare, S.
Lancet Oncol. 2017 Oct;18(10):1397-1410.
https://www.ncbi.nlm.nih.gov/pubmed/28882536 
18/10/2017
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study
Phillips, E. H. Nash, S. Adedayo, T. Whelan, C. J. Fontana, M. Mahmood, S. Lachmann, H. J. Gillmore, J. D. Smith, P. Clifton-Hadley, L. Hawkins, P. N. Wechalekar, A. D.
Amyloid. 2017 Oct 6:1-3.

https://www.ncbi.nlm.nih.gov/pubmed/28984490
06/10/2017
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R. Davies, A. Ando, K. Klapper, W. Opat, S. Owen, C. Phillips, E. Sangha, R. Schlag, R. Seymour, J. F. Townsend, W. Trneny, M. Wenger, M. Fingerle-Rowson, G. Rufibach, K. Moore, T. Herold, M. Hiddemann, W.
N Engl J Med 2017 Oct 5;377(14):1331-1344

https://www.ncbi.nlm.nih.gov/pubmed/28976863
05/10/2017
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: Results of the UK NCRI R-CHOP-14 versus 21 trial
Gleeson, M., Counsell, N., Cunningham, D., Chadwick, N., Lawrie, A., Hawkes, E. A., McMillan, A., Ardeshna, K. M., Jack, A., Smith, P., Mouncey, P., Pocock, C., Radford, J. A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J. and Linch, D.

Ann Oncol. 2017 Oct1;28(10):2511-2516. doi: 10.1093/annonc/mdx353. https://www.ncbi.nlm.nih.gov/pubmed/28961838
01/10/2017
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, et al.
AnnOncol. 2017;28(10):2472-80.
01/10/2017
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study
Roncolato, F. T., Joly, F., O'Connell, R., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J. S., Heitz, F., Feeney, A., Berton-Rigaud, D., Stockler, M. R., King, M., Friedlander, M. and group, Gcig Symptom Benefit
https://www.ncbi.nlm.nih.gov/pubmed/28596446
22/09/2017
Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer
Read ML, Fong JC, Modasia B, Fletcher A, Imruetaicharoenchoke W, Thompson RJ, et al.

Oncogene. 2017 Sep 14;36(37):5296-5308

https://pubmed.ncbi.nlm.nih.gov/28504713/
14/09/2017
Patient experience and perceived acceptability of whole-body magnetic resonance imaging for staging colorectal and lung cancer compared with current staging scans: a qualitative study
Evans, R. Taylor, S. Janes, S. Halligan, S. Morton, A. Navani, N. Oliver, A. Rockall, A. Teague, J. Miles, A. Streamline trials, investigators
BMJ Open. 2017 Sep 6;7(9):e016391. https://www.ncbi.nlm.nih.gov/pubmed/28882915 
06/09/2017
The impact of cardiac radiation dosimetry on survival following radiotherapy for non-small cell lung cancer
Vivekanandan S, Landau DB, Counsell N, Warren DR, Khwanda A, Rosen SD, et al.
IntJ Radiat Oncol Biol Phys. 2017;99(1):51-60.
01/09/2017
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litiere S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G
Pediatr Blood Cancer. 2017 Aug,64(8). https://pubmed.ncbi.nlm.nih.gov/28111876/
01/08/2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al.
LancetOncol. 2017;18(8):1009-21.
01/08/2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
Wheeler GM, Sweeting MJ, Mander AP

Stat Med. 2017;36(16):2499-513.

https://www.ncbi.nlm.nih.gov/pubmed/28295513
20/07/2017
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
Stark DP, Cook A, Brown JM, Brundage MD, Embleton AC, Kaplan RS, et al.
Cancer.2017;123(14):2752-61.
15/07/2017
Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study
Bray TJP, Singh S, Latifoltojar A, Rajesparan K, Rahman F, Narayanan P, Naaseri S, Lopes A, Bainbridge A, Punwani S, Hall-Craggs MA
PLoS One. 2017 July 3,12(7):e0180562. https://www.ncbi.nlm.nih.gov/pubmed/28672007
03/07/2017
Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A, Patel A, Neal B, Peiris D, Thakkar J, Chalmers J, Nelson M, Reid C, Hillis GS, Woodward M, Hilmer S, Usherwood T, Thom S, Rodgers A
Hypertension. 2017 July,70(1):85-93
https://www.ncbi.nlm.nih.gov/pubmed/28584013
01/07/2017
GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas
Seddon B, Strauss S, Whelan J, Leahy MG, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal G, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S
Lancet Oncol. 2017. (in press)
01/07/2017
Obinutuzumab-Based Induction and Maintenance in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM study
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour J, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W
N Engl J Med. 2017. (in press)
01/07/2017
Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
Kuhnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, et al.

Ann Oncol. 2017;28(7):1540-6.

https://pubmed.ncbi.nlm.nih.gov/28398499/
01/07/2017
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study
Wood, G., Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T. and Bridgewater, J.
https://www.ncbi.nlm.nih.gov/pubmed/28252533
28/06/2017
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, Woolston J, Thomson AM, Tsiountsioura M, Cole D, Mead BR, Irvine L, Turner D, Suhrcke M, Pimpin L, Retat L, Jaccard A, Webber L, Cohn SR, Jebb SA
Lancet. 2017 June 3,389(10085):2214-25
https://www.ncbi.nlm.nih.gov/pubmed/28478041
03/06/2017
Tracking the Evolution of Non-Small-Cell Lung Cancer
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C. TRACERx Consortium
N Engl J Med. 2017(376):2109-2121.
https://www.ncbi.nlm.nih.gov/pubmed/28445112
01/06/2017
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani et al
N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.
01/06/2017
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
Dehbi HM, Royston P, Hackshaw A

BMJ. 2017 May25;357:j2250. doi: 10.1136/bmj.j2250. https://www.ncbi.nlm.nih.gov/pubmed/28546261
25/05/2017
Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial
Hirst Y, Skrobanski H, Kerrison RS, Kobayashi LC, Counsell N, Djedovic N, Ruwende J, Stewart M, von Wagner C
Br J Cancer. 2017 May 23,116(11):1408-1414. : https://www.ncbi.nlm.nih.gov/pubmed/28441381 
23/05/2017
Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI
Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, et al

New Engl J Med 017May 11;376(19):1824-1834. 

https://pubmed.ncbi.nlm.nih.gov/28317458/
11/05/2017
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A
J Clin Oncol. 2017;35(14):1506-14
https://www.ncbi.nlm.nih.gov/pubmed/28240967
10/05/2017
Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L)
Taylor, S. A., Mallett, S., Miles, A., Beare, S., Bhatnagar, G., Bridgewater, J., Glynne-Jones, R., Goh, V., Groves, A. M., Janes, S. M., Koh, D. M., Morris, S., Morton, A., Navani, N., Oliver, A., Padhani, A. R., Punwani, S., Rockall, A. G. and Halligan, S.
https://www.ncbi.nlm.nih.gov/pubmed/28464835
02/05/2017
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ
Leukemia. 2017;31(5):1087-1095.
https://www.ncbi.nlm.nih.gov/pubmed/28126984
01/05/2017
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Quesne JL, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Bakir MA, GrOnroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie P, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJ, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C
Nature. 2017 Apr 26,545(7655):446-451.
https://www.ncbi.nlm.nih.gov/pubmed/28445469
26/04/2017
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Abbosh C et al. .
Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364.
26/04/2017
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al

Nature. 2017Apr 26;545(7655):446-51
26/04/2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA
Immunity. 2017 Apr 18;46(4):577-586.
https://www.ncbi.nlm.nih.gov/pubmed/28410988
18/04/2017
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, Valle JW
BMC Cancer. 2017 April 12;17(1):262
https://www.ncbi.nlm.nih.gov/pubmed/28403829
12/04/2017
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups
Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, et al.
Br J Haematol. 2017 Apr;177(1):106-115.
01/04/2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA, Melanoma TC, Renal TC, Lung TC, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA
Immunity. 2017,46(4):577-86
01/04/2017
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
King J, Palmer DH, Johnson P, Ross P, Hubner RA, Sumpter K, et al.

Clin Oncol (R Coll Radiol). 2017;29(4):256-62.
01/04/2017
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET)
Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, Middleton G, Ahmed S, Hicks J, Crosse B, Napier M, Singer JM, Ferry D, Lewanski C, Forster M, Rolls SA, Capitanio A, Rudd R, Iles N, Ngai Y, Gandy M, Lillywhite R, Hackshaw A
J Clin Oncol. 2017;35(4):402-111
https://www.ncbi.nlm.nih.gov/pubmed/27893326
01/04/2017
Clinical Endpoints in Clinical Trials of Chemoradiation for Anal Cancer
Glynne-Jones R, Meadows H, Lopes A, Adams R
Lancet Oncol. 2017 Apr;18(4):e218-e227.   https://www.ncbi.nlm.nih.gov/pubmed/28368260
01/04/2017
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L
Lancet Oncol. 2017 March,18(3):347-56. https://www.ncbi.nlm.nih.gov/pubmed/28209296
01/03/2017
Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials
Raine R, Atkin W, von Wagner C, Duffy S, Kralj-Hans I, Hackshaw A, et al.
Programme Grants for Applied Research; NIHR Journals Library. Southampton (UK) 2017.
01/03/2017
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A
JAMA Oncol. 2017;3(1):58-66

https://www.ncbi.nlm.nih.gov/pubmed/27584578
01/03/2017
Publishing interim results of randomised clinical trials in peer-reviewed journals
Counsell N, Biri D, Fraczek J, Hackshaw A
Clin Trials. 2017 Feb,14(1):67-77. https://www.ncbi.nlm.nih.gov/pubmed/27889701
01/02/2017
Investigating Subgroup Effects in Randomized Clinical Trials
Dehbi HM, Hackshaw A
J Clin Oncol. 2017 Jan 10,35(2):253-4. https://www.ncbi.nlm.nih.gov/pubmed/28056207
10/01/2017
Dose specification for hippocampal sparing whole brain radiotherapy (HS WBRT): considerations from the UK HIPPO trial QA programme
Megias D, Phillips M, Clifton-Hadley L, Harron E, Eaton DJ, Sanghera P, Whitfield G
Br J Radiol. 2017;90(1071):20160829
https://www.ncbi.nlm.nih.gov/pubmed/28059560
01/01/2017
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review
Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA
Gynecol Oncol. 2017;144(1):57-60.
https://www.ncbi.nlm.nih.gov/pubmed/27825669
01/01/2017
Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches
Lanceley A, Berzuini C, Burnell M, Gessler S, Morris S, Ryan A, Ledermann JA, Jacobs I
Int J Gynecol Cancer. 2017;27(1):59-68

https://www.ncbi.nlm.nih.gov/pubmed/28002208
01/01/2017
Improving uptake of flexible sigmoidoscopy screening: a randomized trial of nonparticipant reminders in the English Screening Programme
Kerrison RS, McGregor LM, Marshall S, Isitt J, Counsell N, Rees CJ, von Wagner C
Endoscopy. 2017;49(1):35-43
https://www.ncbi.nlm.nih.gov/pubmed/27997965
01/01/2017
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
Patel B, Kirkwood AA, Dey A, Marks DI, McMillan AK, Menne TF, Micklewright L, Patrick P, Purnell S, Rowntree CJ, Smith P, Fielding AK
Leukemia. 2017 Jan;31(1):58-64.
https://www.ncbi.nlm.nih.gov/pubmed/27480385
01/01/2017
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
Popat S, Hughes L, O'Brien M, Ahmad T, Lewanski C, Dernedde U, et al.
Journalof Thoracic Oncology. 2017;12(1):S1215-S6.

https://doi.org/10.1016/j.jtho.2016.11.1713. 
01/01/2017
Publications in 2016
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK
Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, Hasan J, Edmondson R, Winter-Roach B, Kitchener HC, Mould T, Hutson R, Hall G, Clamp AR, Perren T, Ledermann J, Jayson GC
Clin Oncol (R Coll Radiol). 2016,28(12):760-5.
01/12/2016
A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening
Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW
Br J Cancer. 2016,115(12):1479-86
01/12/2016
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
UK CLL Forum
Haematologica. 2016 Dec;101(12):1563-1572
01/12/2016
Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT)
Beeken RJ, Croker H, Heinrich M, Smith L, Williams K, Hackshaw A, Hines J, Machesney M, Krishnaswamy M, Cavanagh S, Roylance R, Hill A, Pritchard-Jones K, Wardle J, Fisher A
BMJ Open. 2016,6(11):e011646
01/11/2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Ledermann JAH, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Fielding, A., Bennett, B., Parry, D., Spencer, S., Mann, H., Matulonis, U
Br J Cancer. 2016,115(11):1313-20
01/11/2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U
Lancet Oncol. 2016,17(11):1579-89
01/11/2016
A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
Wheeler GM, Sweeting MJ, Mander AP
PLoS One. 2016,11(7):e0159026
01/11/2016
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis
De Ruysscher D, Lueza B, Le Pechoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP, RTT-SCLC Collaborative Group
Ann Oncol. 2016,27(10):1818-28
01/10/2016
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.
Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJ, McGranahan N, Rosenthal R, Straten PT, Szallasi Z, Svane IM, Swanton C, Quezada SA, Jakobsen SN, Eklund AC, Hadrup SR.
Nat Biotechnol. 2016 Oct;34(10):1037-1045. doi: 10.1038/nbt.3662. Epub 2016 Aug 29. PMID: 27571370.
01/10/2016
Quality of life, long-term survivors and long-term outcome from the ABC-02 study
Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H
Br J Cancer. 2016,114(9):965-71
01/09/2016
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320
Townsend W, Johnson RJ, Pottinger BT, Counsell N, Smith P, Chadwick H, Evans K, Wickham C, Rudin CE, Group UNLCS
Leuk Lymphoma. 2016,57(9):2232-4
01/09/2016
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations
Miller RE, Ledermann JA
Clin Adv Hematol Oncol. 2016,14(9):704-11
01/09/2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL, Portec study group
Lancet Oncol. 2016,17(8):1114-26
17/08/2016
Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin
Watkins RJ, Imruetaicharoenchoke W, Read ML, Sharma N, Poole VL, Gentilin E, Bansal S, Bosseboeuf E, Fletcher R, Nieto HR, Mallick U, Hackshaw A, Mehanna H, Boelaert K, Smith VE, McCabe CJ
J Clin Endocr Metab. 2016,101(12):4551-63
01/08/2016
Molecular profiling of circulating tumour cells (CTCs) in non-small cell lung cancer within the TRACERx study of intratumoural heterogeneity and evolution.
S. Gulati, D.G. Rothwell, D. Burt, B. Mesquita, C. Wirth, G. Wilson, J. Pierce, G. Brady, C. Swanton, C. Dive.
EACR24 Poster Sessions / European Journal of Cancer 61, Suppl. 1 (2016) S9–S218.
10/07/2016
Use of a 12 months' self-referral reminder to facilitate uptake of bowel scope (flexible sigmoidoscopy) screening in previous non-responders: a London-based feasibility study
Kerrison RS, McGregor LM, Marshall S, Isitt J, Counsell N, Wardle J, von Wagner C
Br J Cancer. 2016,114(7):751-8
01/07/2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S
N Engl J Med. 2016,374(25):2419-29
23/06/2016
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer
Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, Garcia-Alonso A, Harden SV, Hicks JD, Hughes SR, Illsley MC, Khan I, Laurence V, Malik Z, Mayles H, Mayles WP, Miles E, Mohammed N, Ngai Y, Parsons E, Spicer J, Wells P, Wilkinson D, Fenwick JD
Int J Radiat Oncol Biol Phys. 2016,95(5):1367-77
01/05/2016
Improving target volume delineation in intact cervical carcinoma: Literature review and step-by-step pictorial atlas to aid contouring
Eminowicz G, Hall-Craggs M, Diez P, McCormack M
Pract Radiat Oncol. 2016,6(5):e203-13.
01/05/2016
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Clifton-Hadley L, Wanek K, Krell D, Jeffries S, Khan I, Smith P, Mulholland P
PLoS One. 2016,11(5):e0156369
01/05/2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial
Gleeson M, Hawkes EA, Cunningham D, Chadwick N, Counsell N, Lawrie A, Jack A, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Linch D
Br J Haematol. 2016,175(4):668-72
01/04/2016
EP-1949: Developing a Radiotherapy Quality Assurance programme as part of the HIPPO trial (NCT02147028)
Megias, D; Yang, H; Sanghera, P; Phillips, M; Senthil, L; Jackson, A; Whitfield, G

Radiother Oncol. 2016,119(1):S925 
01/04/2016
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J. S. Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A. Wilson, Nicolai J. Birkbak, Crispin T. Hiley, Thomas B. K. Watkins, Seema Shafi, Nirupa Murugaesu, Richard Mitter, Ayse U. Akarca, Joseph Linares, Teresa Marafioti, Jake Y. Henry, Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Dirk Schadendorf, Levi A. Garraway, Vladimir Makarov, Naiyer A. Rizvi, Alexandra Snyder, Matthew D. Hellmann, Taha Merghoub, Jedd D. Wolchok, Sachet A. Shukla, Catherine J. Wu, Karl S. Peggs, Timothy A. Chan, Sine R. Hadrup, Sergio A. Quezada, Charles Swanton.
Science. 2016 Mar 25; 351 (6280); 1463-1469. DOI: 10.1126/science.aaf1490.
25/03/2016
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fossa A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW
Blood. 2016,127(12):1531-8
24/03/2016
The dosimetric impact of target volume delineation variation for cervical cancer radiotherapy
Eminowicz G, Rompokos V, Stacey C, McCormack M
Radiother Oncol. 2016,120(3):493-9
01/03/2016
Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours
Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A, Alrifai D, Nsiah-Sarbeng P, Gillmore R, Mayer A, Thirlwell C, Sarker D, Valle JW, Meyer T
Endocr Relat Cancer. 2016,23(7):563-70
01/03/2016
Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening
Raine R, Duffy SW, Wardle J, Solmi F, Morris S, Howe R, Kralj-Hans I, Snowball J, Counsell N, Moss S, Hackshaw A, von Wagner C, Vart G, McGregor LM, Smith SG, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Atkin W
Br J Cancer. 2016,114(3):321-6.
01/03/2016
Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group
Shankar AG, Kirkwood AA, Depani S, Bianchi E, Hayward J, Ramsay AD, Hall GW
Br J Haematol. 2016,173(3):421-31
01/03/2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA
J Thorac Oncol. 2016,11(3):312-23
01/03/2016
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial
Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D
Haematologica. 2016,101(2):235-40.
01/02/2016
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D.
Haematologica. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26.
01/02/2016
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.
Int J Gynecol Cancer. 2016 Jan;26(1):2-30. doi: 10.1097/IGC.0000000000000609.
01/01/2016
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up†.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.
Ann Oncol. 2016 Jan;27(1):16-41. doi: 10.1093/annonc/mdv484. Epub 2015 Dec 2.
01/01/2016
PET-CT for staging & early response: results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033).
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW.
Blood. 2016 Jan 8. pii: blood-2015-11-679407. [Epub ahead of print]
01/01/2016
Research in progress-LungSEARCH: a randomised controlled trial of surveillance for the early detection of lung cancer in a high-risk group
Spiro SG, Hackshaw A, on behalf of the LungSEARCH Collaborative Group
Thorax. 2016,71(1):91-3.
01/01/2016
Incoherent dose-escalation in phase I trials using the Escalation with Overdose Control approach
Wheeler GM
Statistical Papers. 2016; 1-11. doi:10.1007/s00362-016-0790-7
01/01/2016
Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials
Wardle J, von Wagner C, Kralj-Hans I, Halloran SP, Smith SG, McGregor LM, Vart G, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Counsell N, Morris S, Duffy SW, Hackshaw A, Moss S, Atkin W, Raine R
Lancet. 2016,387(10020):751-9
01/01/2016
Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial
McGregor LM, von Wagner C, Atkin W, Kralj-Hans I, Halloran SP, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Thomas MC, Smith SG, Vart G, Howe R, Counsell N, Hackshaw A, Morris S, Duffy SW, Raine R, Wardle J
Gastroent Res Pract. 2016
01/01/2016
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer
Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS
Oncology. 2016,91(1):48-54
01/01/2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, Gonzalez-Martin A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MK, ICON6 collaborators.
Lancet. 2016,387(10023):1066-74.
01/01/2016
Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
Khan MS, Kirkwood AA, Tsigani, T., Lowe, H., Goldstein, R., Hartley, J.A., Caplin, M.E., Meyer, T
Clinical Cancer Research. 2016,22(1):79-85
01/01/2016
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW
BMC Cancer. 2016,16:153
01/01/2016
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al
Ann Oncol. 2016,27(1):134-40
01/01/2016
Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial
Jenkinson S, Kirkwood AA, Goulden N, Vora A, Linch DC, Gale RE
Leukemia. 2016,30(1):39-47
01/01/2016
Text Reminders in Colorectal Cancer Screening (TRICCS): Protocol for a randomised controlled trial
62. Hirst Y, Kerrison R, Kobayashi LC, Counsell N, Djedovic N, Ruwende J, Stewart M, von Wagner C
BMC Public Health. 2016,16:74
01/01/2016
Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol
Heinrich M, Fisher A, Paton B, McCourt O, Beeken RJ, Hackshaw A, Wardle J, Yong K
BMC Cancer. 2016,16:387
01/01/2016
Publications in 2015
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO–ESGO–ESTRO Endometrial Consensus Conference Working Group.
Radiother Oncol. 2015 Dec;117(3):559-81. doi: 10.1016/j.radonc.2015.11.013. Epub 2015 Dec 9.
01/12/2015
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
Ledermann JA, El-Khouly F.
Br J Cancer. 2015 Dec 15;113 Suppl 1:S10-6. doi: 10.1038/bjc.2015.395.
01/12/2015
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M, Bacchus investigators
BMC Cancer. 2015,15:764
23/10/2015
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
Ledermann JA, Canevari S, Thigpen T.
Ann Oncol. 2015 Oct;26(10):2034-43. doi: 10.1093/annonc/mdv250. Epub 2015 Jun 10.
01/10/2015
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.
J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.
01/10/2015
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: ABC-02 and BT-22 studies
Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T, Wasan H, Valle J, Bridgewater J
Ann Oncol. 2015,26(9):1910-6
26/09/2015
European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners--First Update 2015.
du Bois A, Reuss A, Pujade-Lauraine E, Pignata S, Ledermann J, Casado A, Sehouli J, Mirza M, Colombo N, Marth C, Witteveen E, Del Campo J, Calvert P, Aravantinos G, Vardar MA, van der Zee AG, Korach J, Taskiran C, Fehr M, Glasspool R, Pfisterer J, Cibula D, Vergote I; member trial groups of the European Network of Gynaecological Oncological Trial Groups (ENGOT).
Int J Gynecol Cancer. 2015 Sep;25(7):1328-30. doi: 10.1097/IGC.0000000000000478.
01/09/2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA
Lancet Oncol. 2015,16(8):967-78.
16/08/2015
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer
Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A
J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.
04/08/2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.
01/08/2015
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).
McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L.
Mod Pathol. 2015 Aug;28(8):1101-22. doi: 10.1038/modpathol.2015.77. Epub 2015 Jun 19.
01/08/2015
The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.
Marth C, du Bois A, Schauer C, du Bois A, Casado A, Vergote I, del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D.
Int J Gynecol Cancer. 2015 Jul;25(6):1094-5. doi: 10.1097/IGC.0000000000000446.
01/07/2015
An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C, Ledermann JA, Benedetti Panici P.
Expert Opin Investig Drugs. 2015;24(9):1163-83. doi: 10.1517/13543784.2015.1072168. Epub 2015 Jul 24.
01/07/2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA
Lancet Oncol. 2015 Jul 10. pii: S1470-2045(15)00139-4. doi: 10.1016/S1470-2045(15)00139-4. [Epub ahead of print]
01/07/2015
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
Khan I, Morris S, Hackshaw A, Lee SM
BMJ Open. 2015,5(7):e006733
01/07/2015
Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - A review of clinical outcome based on the histological variants
Shankar AG, Kirkwood AA, Hall GW, Hayward J, O'Hare P, Ramsay A
Br J Haematol. 2015
26/06/2015
The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma
Venturelli S, Dalla Pria A, Stegmann K, Smith P, Bower M
Br J Cancer. 2015,113(6):861-3
01/06/2015
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
Matulonis UA, Oza AM, Ho TW, Ledermann JA.
Cancer. 2015 Jun 1;121(11):1737-46. doi: 10.1002/cncr.29082.
01/06/2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S
N Engl J Med. 2015,372(17):1598-607
23/04/2015
Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J, Harter P, Gourley C.
Lancet Oncol. 2015 Apr;16(4):e158. doi: 10.1016/S1470-2045(15)70153-1.
01/04/2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S.
N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.
01/04/2015
Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control
Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, Khurrum KF, Leung EY, Dowson S, Webber L, Khan I, Ennis D, Syed N, Crook TR, Brenton JD, Lockley M, McNeish IA
Mol Oncol. 2015 Apr;9(4):791-805
01/04/2015
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer
Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ, Short SC, Freeman A, Powles T, Hoskin PJ, West CM, Kelly JD
Int J Cancer. 2015,136(3):709-20
01/03/2015
duplicate
duplicate


03/02/2015
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, Liefers GJ, Putter H, van de Velde CJ
Lancet Oncol. 2015,16(2):200-7
01/02/2015
New clinical research strategies for rare gynecologic malignancies.
Ray-Coquard I, Pujade-Lauraine E, Ledermann JA.
Curr Opin Obstet Gynecol. 2015 Feb;27(1):53-7. doi: 10.1097/GCO.0000000000000144.
01/02/2015
Planning an Academic Clinical Trial.
Champion KM, Jones GR.
Methods Mol Biol. 2015;1317:287-313. doi: 10.1007/978-1-4939-2727-2_16.
01/01/2015
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Kuku S, Proctor I, Loddo M, Kadalayil L, KhoshZaban M, McCormack M, Ledermann J.
Int J Gynecol Cancer. 2015 Jan 23. [Epub ahead of print]
01/01/2015
A Phase II Study to Determine the Efficacy and Safety of Oral Treosulfan in Patients With Advanced Pre-Treated Ewing Sarcoma ISRCTN11631773
Michelagnoli M, Whelan J, Forsyth S on behalf of the OTIS Trial Management Group, Site Investigators
Pediatr Blood Cancer 2015;62:158–159
01/01/2015
Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)
Okasha D, Kirkwood A, Copland M, Lawrie E, McMillan A, Menne TF, Morley N, Rowntree C, Richardson DS, Smith P, Fielding AK, Marks D
Blood. 2015,126(23):733
01/01/2015
Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease
Lamarca A, Benafif S, Ross P, Bridgewater J, Valle JW
Eur J Cancer. 2015,51(13):1694-703
01/01/2015
Publications in 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix.
Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, Mahner S, Provencher DM, Mileshkin L, Åvall-Lundqvist E, Pautier P, Reed NS, Fujiwara K.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S102-8. doi: 10.1097/IGC.0000000000000262.
01/11/2014
International Journal of Gynecological Cancer. Editorial.
Ray-Coquard I, Ledermann J.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S2-4. doi: 10.1097/IGC.0000000000000234.
01/11/2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.
Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249.
01/11/2014
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D, Konishi I, Covens A, Ledermann J, Mezzanzanica D, Steer C, Millan D, McNeish IA, Pfisterer J, Kang S, Gladieff L, Bryce J, Oza A.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S20-5. doi: 10.1097/IGC.0000000000000289.
01/11/2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma
Ledermann JA, Luvero D, Shafer A, O'Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9. doi: 10.1097/IGC.0000000000000296.
01/11/2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I.
Ann Oncol. 2014 Oct;25(10):1988-95. doi: 10.1093/annonc/mdu363. Epub 2014 Jul 28.
01/10/2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
McNeish I, Ledermann J, Webber L, James L, Kaye S, Hall M, Hall G, Clamp A, Earl H, Banerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I.
Ann Oncol. 2014 Oct;25(10):1988-95. doi: 10.1093/annonc/mdu363.
01/10/2014
Maintenance therapy in ovarian cancer
Khalique S, Hook JM, Ledermann JA
Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110.
01/09/2014
ACT II Study Group. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II tria
Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D
Ann Oncol. 2014 Aug;25(8):1616-22. doi: 10.1093/annonc/mdu188. Epub 2014 May 14.
01/08/2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A,Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U
Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.
01/07/2014
Chronicle: Results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (Xelox) versus control
Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, Ledermann J, Sebag-Montefiore D
Ann Oncol. 2014 Jul;25(7):1356-62. doi: 10.1093/annonc/mdu147. Epub 2014 Apr 8.
01/07/2014
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study
Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornas
PLoS Biol. 2014 Jul 8;12(7):e1001906. doi: 10.1371/journal.pbio.1001906
01/07/2014
Optimal treatment of early-stage ovarian cancer
Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart A; ICON1 collaborators
Ann Oncol. 2014 Jun;25(6):1165-71. doi: 10.1093/annonc/mdu116. Epub 2014 Mar 14.
01/06/2014
Impact of diabetes mellitus and renal insufficiency on 5-year mortality following coronary artery bypass graft surgery: a cohort study of 4869 UK patients
Gallagher S, Kapur A, Lovell MJ, Jones DA, Kirkwood A, Hassan S, Archbold RA, Wragg A, Uppal R, Yaqoob MM
Eur J Cardiothorac Surg. 2014,45(6):1075-81
01/06/2014
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma – results of the UK HD3 relapse treatment strategy
Shankar A, Haywood J, Kirkwood A, McCarthy K, Hewitt M, Morland B, Daw S
Br J Haematol. 2014,165(4):534–44
01/05/2014
Tumour- and treatment-related colostomy rates following Mitomycin or Cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial
Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D; on behalf of the ACT II study group
Ann Oncol. 2014 May 14. pii: mdu188. [Epub ahead of print]
01/05/2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Ardeshna KMQ, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C.F., Miall, F., Cunningham, D., Davies, J., Jack, A., Stephens, R., Walewski, J., Ferhanoglu, B., Bradstock, K., Linch, D.C
Lancet Oncol. 2014,15(4):424-35
15/04/2014
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial
Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I
Lancet Oncol. 2014,15(4):457-63
15/04/2014
Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges.
Ledermann JA, Ray-Coquard I.
Am Soc Clin Oncol Educ Book. 2014:e282-6. doi: 10.14694/EdBook_AM.2014.34.e282.
01/04/2014
End points in anal cancer: hopes for a common language
Glynne-Jones R, Adams RA, Jitlal M, Meadows H
J Clin Oncol. 2014 Apr 20;32(12):1281-2
01/04/2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC
Lancet Oncol. 2014 Apr;15(4):424-35.
01/04/2014
Better therapeutic trials in ovarian cancer
Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.
J Natl Cancer Inst. 2014 Apr;106(4)
01/04/2014
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial
Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, Coltart S, Illidge T, Madhavan K, Brammer C, Diez P, Jack A, Syndikus I
Lancet Oncol. 2014 Apr;15(4):457-63.
01/04/2014
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983
Tanis E, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J, Ruers TJ.
Eur J Cancer. 2014 Mar;50(5):912-9.
01/03/2014
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T.
Ann Oncol. 2014 Feb;25(2):391-8
01/02/2014
Biomarkers and response to bevacizumab--response
Collinson F, Hutchinson M, Craven RA, Cairns DA, Alexandre Z, Wind TC, Gahir N, Messenger MP, Jackson S, Thompson D, Adusei C, Ledermann J, Hall G,Jayson GC, Selby PJ, Banks RE
Clin Cancer Res. 2014 Feb 15;20(4):1058. doi: 10.1158/1078-0432.CCR-13-3269.
01/02/2014
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial
Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D.
J Clin Oncol. 2014 Feb 1;32(4):282-7
01/02/2014
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases
Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, Wadsworth C, Ngai Y, Hackshaw A, Faivre-Finn C
J Natl Cancer Inst. 2014 Jul 16;106(7). pii: dju151. doi: 10.1093/jnci/dju151. Print 2014 Jul.
01/01/2014
Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges
Ledermann JA, Ray-Coquard I
Am Soc Clin Oncol Educ Book. 2014:e282-6. doi: 10.14694/EdBook_AM.2014.34.e282.
01/01/2014
A non-linear Beta-Binomial regression model for mapping QLQC-30 to the EQ-5D in lung cancer patients: A comparison with existing approaches
I Khan, S Morris
Quality of Life Research 2014 (in press)
01/01/2014
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee JM, Ledermann JA, Kohn EC.
Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384.
01/01/2014
SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status
Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C, Snee M
Eur J Cancer. 2014,50(17):2939-49
01/01/2014
Improving research on the efficacy, effectiveness, and harms of traditional chinese medicine
Tang JL, Hackshaw A, Lao LX, Liu BY, Chung VC
Evid Based Complement Alternat Med. 2014,2014:657679
01/01/2014
Publications in 2013
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA.
Ann Oncol. 2013 Dec;24(12):3028-34
01/12/2013
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Illidge T, Chan C, Counsell N, Morris S, Scarisbrick J, Gilson D, Popova B, Patrick P, Smith P, Whittaker S, Cowan R.
Br J Cancer. 2013 Nov 12;109(10):2566-73
01/11/2013
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T.
Ann Oncol. 2013 Oct;24(10):2565-70
01/10/2013
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
01/10/2013
Application of methods for central statistical monitoring in clinical trials
Kirkwood AA, Cox T, Hackshaw A.
Clin Trials. 2013 Oct;10(5):783-806
01/10/2013
A non-linear beta-binomial regression model for mapping qlqc-30 to the eq-5d in lung cancer patients: a comparison with existing approaches
Khan I, Sarker SJ, Morris S
Trials 2013, 14(Suppl 1):O23
01/10/2013
Well-being after radiation therapy in thyroid cancer
Hackshaw A, Kadalayil L, Mallick U
N Engl J Med. 2013,368(7):685-6
01/07/2013
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework
Sarker SJ, Whitehead A, Khan I.
Comput Methods Programs Biomed. 2013 Jun;110(3):471-89
01/06/2013
PET-CT for staging and early response – results from the Response Adapted Therapy in Advanced Hodgkin Lymphoma (RATHL) study
Sally F Barrington, Michael J O’Doherty, Thomas Roberts, Amy Kirkwood, Zaid Viney, Rebecca Preston, Antonella Franceschetto, Michael Fulham, Marina Cucca, Helen Almquist, Eva Brun, Karin Hjorthaug, Lucy Pike, Donald Sinclair, Peter Johnson.
The 12th International Conference on Malignant Lymphoma, Lugano
01/06/2013
Responses defined by PET-CT imaging: first results from the international Response Adapted Therapy in advanced Hodgkin Lymphoma (RATHL) study.
Johnson, Federico, Fossa, O’Doherty, Roberts, Stevens, Smith, Kirkwood, Berkhan, Trotman, Enblad, D’Amore, Luminari, Viney, Radford, Barrington.
The 12th International Conference on Malignant Lymphoma, Lugano
01/06/2013
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
M. McCormack, L. Kadalayil, A. Hackshaw, M. A. Hall-Craggs, R.P. Symonds, V. Warwick, H. Simonds, I. Fernando, M. Hammond, L. James, A. Feeney, J. A. Ledermann
Br J Cancer. 2013 Jun 25;108(12):2464-9
01/06/2013
A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial
Lee SM, Hackshaw A
Cancer Med. 2013 Jun;2(3):360-6.
01/06/2013
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
Lancet. 2013 May 25;381(9880):1817-26
01/05/2013
Exploiting FOXM1-Orchestrated Molecular Network for Early Squamous Cell Carcinoma Diagnosis and Prognosis
Teh MT, Hutchison IL, Costea DE, Neppelberg E, Liavaag PG, Purdie K, Harwood C, Wan H, Odell EW, Hackshaw A, Waseem A
Int J Cancer. 2013 May 1;132(9):2095-106
01/05/2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D’Sa S, Rabin N, Johnston R, Schey S, Yong K
Eur J Haematol. 2013 May;90(5):420-5
01/05/2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D.
Lancet Oncol. 2013 May;14(6):516-24
01/05/2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenbergh E, Mackinnon S, Chakraverty R
Br J Haematol. 2013,160(5):640-8
01/05/2013
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK.
Br J Cancer. 2013 Apr 2;108(6):1252-9
01/04/2013
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy
Lowry L, Smith P, Cunningham D, Linch DC.
J Geriatr Oncol. 2013 Apr;4(2):134-40.
01/04/2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding AK, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs KS, Thomson KJ, Vandenberghe E, Mackinnon S, Chakraverty R.
Br J Haematol. 2013 Mar;160(5):640-8
01/03/2013
Circulating tumor cells as prognostic markers in neuroendocrine tumors
Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T
J Clin Oncol. 2013,31(3):365-72
01/03/2013
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework. Computer methods and programs in biomedicine
Sarker SJ, Whitehead A, Khan I
Computer methods and programs in biomedicine. 2013,110(3):471-89
01/03/2013
Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I)
Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM, Jitlal M; United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial Working Party.
Cancer. 2013 Feb 15;119(4):748-55
01/02/2013
Capturing data on colostomy formation in anal cancer
Glynne-Jones R, Beare S, Begum R, Kadalayil L
J Clin Oncol. 2013,31(1):164
01/01/2013
Publications in 2012
Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma
Pereira SP, Aithal GP, Ragunath K, Devlin J, Owen F, Meadows H.
Photodiagnosis Photodyn Ther. 2012 Dec;9(4):287-92.
01/12/2012
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C
Lancet. Nov 2012; 13:11: 1161-1170
01/11/2012
Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
Hardwick N, Ledermann JA, Aitkens E, Chain B
Cancer Immunol Immunother. 2012 Nov;61(11):1929-39
01/11/2012
Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B; for the EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG)
Ann Oncol. 2012 Oct;23(10):2619-26.
01/10/2012
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation
Wong HH, Parkinson C, Ledermann JA, Brenton JD, Merger M, Shaw A, Patterson A, Shafi M, Earl HM.
Gynecol Oncol Case Rep. 2012 Oct 17;3:7-10
01/10/2012
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
Raja FA, Hook JM, Ledermann JA
Cancer Treat Rev. 2012 Oct;38(6):662-72
01/10/2012
Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies
Jitlal M, Khan I, Lee SM, Hackshaw A
Br J Cancer. 2012 Sep 4;107(6):910-7
01/09/2012
Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma
N Rabin, L Percy, I Khan, J Quinn, S D’Sa, K Yong
Br J Haematol. 2012 Aug;158(4):499-50
01/08/2012
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P
Radiother Oncol. 2011 Jul;100(1):86-92
01/07/2012
Attitudes to participation in a lung cancer screening trial: a qualitative study
Patel D, Akporobaro A, Chinyanganya N, Hackshaw A, Seale C, Spiro S, Griffiths C
Thorax. 2012 May;67(5):418-25
01/05/2012
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A
N Engl J Med. 2012 May 3;366(18):1674-85
01/05/2012
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery
Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA
Int J Gynecol Cancer. 2012 May;22(4):566-72.
01/05/2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U
N Engl J Med. 2012 Apr 12;366(15):1382-92.
01/04/2012
High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence
Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, Milner J, Cladd H
Int J Radiat Oncol Biol Phys. 2012,82(4):1376-84
01/04/2012
Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo
Mallick U, Harmer C, Hackshaw A, Moss L, IoN Trial Management Group.
Clin Oncol (R Coll Radiol). 2012,24(3):159-61
01/04/2012
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ
Br J Cancer. 2012 Mar 13;106(6):1153-9
01/03/2012
Family history and women with ovarian cancer: is it asked and does it matter?: An observational study
Lanceley A, Eagle Z, Ogden G, Gessler S, Razvi K, Ledermann JA, Side L
Int J Gynecol Cancer. 2012 Feb;22(2):254-9.
01/02/2012
Iodine-stabilized Cu nanoparticle chitosan composite for antibacterial applications
Mallick S, Sharma S, Banerjee M, Ghosh SS, Chattopadhyay A, Paul A
ACS Appl Mater Interfaces. 2012,4(3):1313-23
01/01/2012
Reply to: "Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?"
Meyer T, Kirkwood A, Gillmore R
J Hepatol. 2012,57(1):225-6
01/01/2012
Review of mammographic screening
Hackshaw A
Special issue of Journal of Medical Screening. Editor of Special Issue. 2012,19(1):5-82.
01/01/2012
Benefits and harms of mammography screening
Hackshaw A
BMJ. 2012,344:d8279
01/01/2012
The benefits and harms of mammographic screening for breast cancer: building the evidence base using service screening programmes
Hackshaw A
J Med Screen. 2012,19:1-2.
01/01/2012
Publications in 2011
A phase 3 trial of bevacizumab in ovarian cancer
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators
N Engl J Med. 2011 Dec 29;365(26):2484-96.
01/12/2011
“Mind the Gap” – The impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)
Glynne-Jones R, Sebag-Montefiore D, Adams R, McDonald A, Gollins S, James R, Northover JM, Meadows HM, Jitlal M; UKCCCR Anal Cancer Trial Working Party
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1488-94
01/12/2011
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T
J Hepatol. 2011 Dec; 55(6):1309-16.
01/12/2011
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study
Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Rohatiner AZ, Linch DC
J Clin Oncol. 2011 Nov 1;29(31):4096-104
01/11/2011
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
Ledermann, JA, Hackshaw, A, Kaye, S B, Jayson, G C, Gabra, IH, McNeish, I, Earl, H, Perren, P, Gore, M, Persic, M, Adams, M, James, L, Temple, G, Merger, M and Rustin, G
J Clin Oncol. 2011 Oct 1;29(28):3798-804.
01/10/2011
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
Raja FA, Hook JM, Ledermann JA
Cancer Treat Rev. 2012 Oct;38(6):662-72
01/10/2011
Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls
Hackshaw A, Rodeck C, Boniface S
Hum Reprod Update. 2011 Sep-Oct;17(5):589-604.
01/09/2011
Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer
Ledermann JA, Raja FA
Eur J Cancer. 2011 Sep;47 Suppl 3:S104-15
01/09/2011
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, Ledermann JA
Br J Cancer. 2011 Sep 27;105(7):884-9
01/09/2011
Research and Methods: Interpreting and reporting clinical trials with results of borderline statistical significance
Hackshaw A, Kirkwood A
BMJ. 2011 Jul 4;343:d3340
01/07/2011
Efficacy, safety, and tolerability of sertraline on depressive symptoms in women with comorbid migraine: an open-label study
MacGregor A, Frith A, Hackshaw A
J Clin Psychopharmacol. 2011 Jun;31(3):392-3.
01/06/2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup
Int J Gynecol Cancer. 2011 May;21(4):763-70
01/05/2011
Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference
Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E; participants of 4th Ovarian Cancer Consensus Conference (OCCC); Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG)
Int J Gynecol Cancer. 2011 May;21(4):750-5
01/05/2011
Long-term benefits of 5 years of tamoxifen: 10 year follow up of a large randomised trial in women aged at least 50 years with early breast cancer
Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M
J Clin Oncol. 2011 May 1;29(13):1657-63
01/05/2011
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation
Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S
J Clin Oncol. 2011 Mar 10;29(8):971-8
01/03/2011
Stromal features are predictive of disease mortality in oral cancer patients.
Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana J, Marshall JF, Hart IR, Hackshaw AK, Piper K, Thomas GJ
J Pathol. 2011 Mar;223(4):470-81.
01/03/2011
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma
Barrington SF, MacKewn JE, P. Schleyer, P. K. Marsden, N. G. Mikhaeel, W. Qian, P. Mouncey, P. Patrick, B. Popova, P. Johnson, J. Radford & M. J. O’Doherty
Ann Oncol. 2011 Mar;22(3):739-45
01/03/2011
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%
Mohamedbhai SG, Sibson K, Marafioti T, Kayani I, Lowry L, Goldstone AH, Linch DC, Ardeshna KM
Br J Haematol. 2011 Jan;152(2):175-81
01/01/2011
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H
Lancet. 2011 Jan 1;377(9759):42-51
01/01/2011
Publications in 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J
N Engl J Med. 2010 Apr 8;362(14):1273-81
01/04/2010
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
Vergote IE, Pujade-Lauraine E,Pignata S, Kristensen GB, Ledermann JA, Casado A, Sehouli J, Mirza M, Fossati R, Marth C. Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee Ate GJ, du Bois A
Int J Gynecol Cancer. 2010 Apr;20(3):476-8.
01/04/2010
Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M
Br J Haematol. 2010 Apr;149(2):237-43.
01/04/2010
Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin (FCiSt) for neuroendocrine tumors
Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Buscombe J, Grillo J, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T
Br J Cancer. 2010 Mar 30;102(7):1106-12.
01/03/2010
Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al
Br J Cancer. 2010 Mar 30;102(7):1123-8.
01/03/2010
Chemo-radiotherapy for locally advanced head and neck cancer: ten-year follow up of the UK Head and Neck (UKHAN1) trial
Tobias J, Monson K, Gupta N, MacDougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A
Lancet Oncol. 2010 Jan;11(1):66-74
01/01/2010
Publications in 2009
Tobacco and other diseases. In Tobacco: The Public Health Disaster of the Twentieth Century
Hackshaw AK
Second edition Oxford University Press 2009
01/12/2009
Trial design strategies for vascular-targeted therapy of ovarian cancer
Varughese M.A. and Ledermann J.A
Clinical Ovarian Cancer, 2(1): 2-5
01/12/2009
Randomized double-blind placebo-controlled trial of Thalidomide in combination with Gemcetabine and Carboplatin in advanced non-small-cell lung cancer
Lee SM, Rudd R, Woll P, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A
J Clin Oncol. 2009 Nov 1;27(31):5248-54.
01/11/2009
Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer
Hackshaw A
Expert Opin Pharmacother. 2009 Nov;10(16):2633-9.
01/11/2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
J Clin Oncol. 2009 Nov 10;27(32):5390-6.
01/11/2009
Circulating Angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis
Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer T
Endocr Relat Cancer. 2009 Sep;16(3):967-76
01/09/2009
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized double-blind placebo-controlled trial
Lee SM, Woll P, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Alil K, Jitlal M, Hackshaw A
J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57.
01/08/2009
Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy
Maniaci V, Davidson B, Rolles K, Dhillon P, Hackshaw A, Begent R, Meyer T
Eur J Surg Oncol. 2009 Jun;35(6):617-21.
01/06/2009
Assessment of two novel ventilatory surrogates for use in the delivery of gated/tracked radiotherapy for non-small cell lung cancer
Hughes S, McClelland J, Tarte S, Lawrence D, Ahmad S, Hawkes D and Landau D
Radiother Oncol. 2009 Jun;91(3):336-41.
01/06/2009
Positioning pemetrexed in the treatment of ovarian cancer
Ledermann JA, Stebbing J
Eur J Cancer. 2009 May;45(8):1330-2.
01/05/2009
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO
Sharma R, Cunningham D, Smith P, Robertson G, Dent O and Clarke S.J
BMC Cancer. 2009 May 18;9:153.
01/05/2009
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma
Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, and Williams GH
Clin Cancer Res. 2009 Apr 1;15(7):2417-25
01/04/2009
Publications in 2008
Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244
Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, Smith P, Qian W, Patrick P, Popova B, Pettitt A, Cunningham D, Pettengell R, Sweetenham J, Linch D, Johnson PW.
Blood, 112 (11), 144
01/11/2008
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us